<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004465.pub2" GROUP_ID="VASC" ID="076902100218374194" MERGED_FROM="" MODIFIED="2016-04-12 12:37:48 +0100" MODIFIED_BY="Nicole Martin" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-04-12 12:37:00 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0221" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2016-04-12 12:37:00 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Danshen (Chinese medicinal herb) preparations for acute myocardial infarction</TITLE>
<CONTACT>
<PERSON ID="12346" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Taixiang</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wu</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>txwutx@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL>http://www.chictr.org</URL>
<MOBILE_PHONE>+86 18980604562</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 86507920</PHONE_1>
<PHONE_2>+86 18980604562</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-04-12 12:35:50 +0100" MODIFIED_BY="Nicole Martin">
<PERSON ID="12346" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Taixiang</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wu</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>txwutx@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL>http://www.chictr.org</URL>
<MOBILE_PHONE>+86 18980604562</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 86507920</PHONE_1>
<PHONE_2>+86 18980604562</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13911" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Juan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ni</LAST_NAME>
<SUFFIX/>
<POSITION>MSc Student</POSITION>
<EMAIL_1>nijuankiki@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8544 8570</PHONE_1>
<PHONE_2>+86 28 8542 2082</PHONE_2>
<FAX_1>+86 28 8554 2774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D37FC09A82E26AA20080535FC742FF64" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Jiafu</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wei</LAST_NAME>
<SUFFIX/>
<POSITION>MSc Student</POSITION>
<EMAIL_1>weijiafu@163.com</EMAIL_1>
<EMAIL_2>weijiafu@163.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>West China Hospital, Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 8542 2081</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 8554 2774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-10 13:31:34 +0000" MODIFIED_BY="Karen Hovhannisyan">
<UP_TO_DATE>
<DATE DAY="14" MONTH="2" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="2" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-12 12:37:00 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2016-04-12 12:37:00 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>This is a low priority topic for the CHG. Review includes studies published between 1984 and 2004. No known ongoing studies. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-04-12 12:35:59 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-04-12 12:35:59 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Chinese Cochrane Centre, West China Hospital of Sichuan University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Center for Complementary and Alternative Medicine (NCCAM)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-03-04 10:43:19 +0000" MODIFIED_BY="Karen Hovhannisyan">
<SUMMARY MODIFIED="2008-11-10 13:33:01 +0000" MODIFIED_BY="Karen Hovhannisyan">
<TITLE MODIFIED="2008-11-10 13:33:01 +0000" MODIFIED_BY="Karen Hovhannisyan">Danshen (Chinese medicinal herb) preparations for acute myocardial infarction</TITLE>
<SUMMARY_BODY>
<P>Danshen - a Chinese herbal treatment - is widely used in China in addition to usual western forms of therapy in the treatment of acute myocardial infarction (AMI). However there is no strong evidence to support its use, and few rigorous studies have been conducted. Well designed and conducted randomised controlled trials are needed to provide adequate evidence of its role in the treatment of AMI.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Acute myocardial infarction (AMI) is the most important cause of morbidity from ischaemic heart disease, and is among the leading causes of death in the western world. Danshen, a Chinese herbal medicine, is widely used in China for treatment of several diseases, including AMI.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects (both benefits and harms) of danshen preparations for AMI.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on <I>The Cochrane Library</I> (issue 4, 2006), MEDLINE (1966-2006), EMBASE (1980-2006), and the Chinese Biomedical Database (CBM) (1982-2006). We also handsearched 75 Chinese medical journals.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials (RCTs) lasting at least 7 days were sought. Since it seemed evident that few RCTs were available, we also considered other controlled studies. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Eligibility and trial quality were assessed by three reviewers.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Six studies comprised of 2368 participants were included. Only one trial was judged to be a genuine RCT and showed no statistically significant difference in reduction of total mortality (Peto OR 0.55, 95% CI 0.23 to 1.32), but a quasi-RCT reported a reduced total mortality (Peto OR 0.42, 95% CI 0.23 to 0.77). Pooling these trials yielded an approximate halving of mortality in those patients treated with danshen preparations plus usual care compared with usual care alone (Peto OR 0.46, 95% CI 0.28 to 0.75).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The evidence to support use of danshen preparations is too weak to make any judgement about its effects. Evidence from RCTs is insufficient and of low quality. The safety of danshen preparations is unproven, although some adverse events have been reported. More evidence from high quality trials is needed to support the clinical use of danshen preparations.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>
<B>Description of the condition</B>
<BR/>Acute myocardial infarction (AMI) is due to the formation of an area of necrosis in heart muscle caused by inadequate supply of blood to the muscle, usually as a result of occlusion of a coronary artery (<LINK REF="REF-Burton-1996" TYPE="REFERENCE">Burton 1996</LINK>). After approximately 3 to 6 hours the area of necrotic cardiac muscle reaches its largest size. AMI can lead to death from complications due to cardiogenic shock, cardiac perforation - external or interventricular, embolism, heart failure, papillary muscle rupture, rhythm disturbances or autoimmune pericarditis (<LINK REF="REF-MVS-2002" TYPE="REFERENCE">MVS 2002</LINK>). AMI is the most common cause of morbidity from ischaemic heart disease and is the leading cause of death in the western world. Each year approximately 800,000 to 1.5 million people in the United States experience AMI, and about 213,000 of them die (<LINK REF="REF-MVS-2002" TYPE="REFERENCE">MVS 2002</LINK>, <LINK REF="REF-Herlitz-1989" TYPE="REFERENCE">Herlitz 1989</LINK>, <LINK REF="REF-NHLBI-1992" TYPE="REFERENCE">NHLBI 1992</LINK>). Accurate data on mortality and incidence of AMI in China are not available. Mortality from myocardial infarction varies according to the patient's sex and age. Younger women with AMI have higher 30-day case fatality than men (e.g. &lt; 55 years, women 6.5% versus 4.8% men, P &lt; 0.0001), and men are more likely to die before hospitalisation (<LINK REF="REF-McCann-2001" TYPE="REFERENCE">McCann 2001</LINK>). Currently myocardial infarction can be accurately diagnosed on the basis of clinical history and electrocardiographic (ECG) evidence. If the ECG evidence is unclear then alterations in cardiac enzymes, such as troponin, are used to aid diagnosis. Other cardiac enzymes besides troponins, are used in helping with the diagnosis, e.g. creatine kinase (CK) and CK-MB. Patients are usually admitted to hospital for acute treatment and monitoring, and the certainty of diagnosis of AMI is increased if cardiac enzyme levels show a rise over time. Typically, troponin levels are used with ECG evidence and clinical symptoms to make a diagnosis of AMI (<LINK REF="REF-Brooks-2001" TYPE="REFERENCE">Brooks 2001</LINK>).</P>
<P>
<B>Treatments for the condition<BR/>
</B>Drug therapy for AMI includes thrombolytic therapy, aspirin for its antiplatelet properties and morphine for pain relief as needed. In addition to pharmacotherapy aimed at improving outcomes, supportive actions including admission to a cardiac care unit, 24~36 hours of bed-rest, continuous ECG monitoring, and oxygen therapy are widely used. In some centres, percutaneous transcoronary angioplasty may be used as primary therapy (<LINK REF="REF-MVS-2002" TYPE="REFERENCE">MVS 2002</LINK>). </P>
<P>
<B>Danshen compound<BR/>
</B>Danshen, a Chinese herbal medicine, is widely used in China for treatment of several diseases, including AMI. The main component of danshen compound is the roots of the danshen plant (Latin name <I>Salvia miltiorrhiza</I>). Three other plants are typically also included with it, <I>Crataegus laevigata</I> (hawthorn), <I>Coleus forskohlii </I>(an Indian herb) and <I>Valeriana officinalis </I>(valerian). Various formaulations are shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Typically, danshen is used as one ingredient together with other herbs and water which is then boiled for several hours resulting in a herbal soup, which can be administered as an injection.</P>
<P>
<I>Salvia miltiorrhiza </I>promotes blood circulation and relieves blood stasis (<LINK REF="REF-Bensky-1987" TYPE="REFERENCE">Bensky 1987</LINK>). It also increases the activity of superoxide dismutase in platelets and inhibits platelet aggregation, thus providing protection against pulmonary embolism. Other effects include cholesterol lowering, reduction of endothelial damage, inhibition of lipid peroxidation, and inhibition of noradrenaline induced contraction of the aortic strips by reducing calcium ion mobilisation (<LINK REF="REF-Negard-1996" TYPE="REFERENCE">Negard 1996</LINK>; <LINK REF="REF-Wang-1996" TYPE="REFERENCE">Wang 1996</LINK>; <LINK REF="REF-Wu-1998" TYPE="REFERENCE">Wu 1998</LINK>). Of the other components, <I>Crataegus laevigata </I>lowers blood pressure but can lead to arrhythmia in the ischaemic myocardium (<LINK REF="REF-Garjani-2000" TYPE="REFERENCE">Garjani 2000</LINK>); <I>Valeriana officinalis</I> is used as a sedative, lowers blood pressure and relieves angiospasm (<LINK REF="REF-BHMA-1983" TYPE="REFERENCE">BHMA 1983</LINK>); and <I>Coleus forskohlii</I> inhibits platelet activation, increases the force of contraction of heart muscle and lowers blood pressure. The actions of <I>Crataegus laevigata</I> are thought to be enhanced by <I>Salvia miltiorrhiza </I>and <I>Coleus forskohlii</I>. The relaxing and stress reducing actions of <I>Valeriana officinalis </I>are thought to further enhance the overall effect of danshen compound.</P>
<P>Danshen compound has several functions:<BR/>1. dilation of the coronary arteries, increasing coronary arterial blood flow (<LINK REF="REF-Sang-1979" TYPE="REFERENCE">Sang 1979</LINK>; <LINK REF="REF-Zhen-1997" TYPE="REFERENCE">Zhen 1997</LINK>);<BR/>2. increasing the deformability of white blood cell and reducing their adherence, thus improving the flow of blood (<LINK REF="REF-Liu-2006a" TYPE="REFERENCE">Liu 2006a</LINK>) and protecting the cardiac muscle from ischaemia (<LINK REF="REF-Zhou-1991" TYPE="REFERENCE">Zhou 1991</LINK>); and<BR/>3. constituent herbs act together to improve peripheral circulation and general well being. In addition, other herbs are sometimes used with danshen compound, for example huangqi (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> provides a glossary of some of the traditional Chinese herbs mentioned in throughout this review.</P>
<P>
<B>Reported side effects of danshen</B>
<BR/>We identified 840 reports about the side effects of danshen compound which include anaphylaxis and anaphylactic shock, stomach discomfort, loss of appetite, pruritus, low blood pressure, dizziness, headache and an increase in the risk of bleeding especially with excessive use. Bleeding may occur in the skin or mucous membranes or menorrhagia may occur. Increased in serum aminotransferase has also been reported (<LINK REF="REF-He-2006" TYPE="REFERENCE">He 2006</LINK>; <LINK REF="REF-Lu-2006" TYPE="REFERENCE">Lu 2006</LINK>; <LINK REF="REF-Zhen-1997" TYPE="REFERENCE">Zhen 1997</LINK>; <LINK REF="REF-Xu-2006" TYPE="REFERENCE">Xu 2006</LINK>).</P>
<P>These herbs may also affect the action of other pharmacological agents:<I> Salvia miltiorrhiza </I>may exaggerate the anticoagulant effect of warfarin (<LINK REF="REF-Chan-2001" TYPE="REFERENCE">Chan 2001</LINK>) and <I>Crataegus laevigata </I> may act synergistically with digitalis, cardiac glycosides and hypotensive drugs. The dosage of medical drugs may need to be modified if used concurrently.</P>
<P>Up to now literally thousands of studies about the effects of danshen compound for AMI have been published, and many purport to show markedly beneficial effects of treatment. This is reflected in the fact that various danshen preparations have been widely used clinically. However, the quality of these studies and the results of clinical trials have not been systematically reviewed and assessed. Accordingly, this review aims to summarise the existing evidence concerning the comparative effects and safety of danshen preparations.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects (harms and benefits) of danshen compound preparations for AMI. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled studies lasting at least 7 days were sought. In the event that few RCTs were available, it was our intention to also consider other controlled studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Participants were adult men and women of any age or ethnic origin with AMI. Diagnosis of AMI was defined as the presence of unequivocal ECG changes and/or unequivocal enzyme changes. The medical history could be typical or atypical.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Danshen compound defined as preparations containing danshen, in various forms (e.g. injection, tablet, decoction) to be compared with: </P>
<UL>
<LI>standard or usual care for acute myocardial infarction;</LI>
<LI>usual pharmacotherapy; </LI>
<LI>placebo; or</LI>
<LI>other Chinese herbs.</LI>
</UL>
<P>
<BR/>We also included those trials in which danshen preparations were used as control.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>Primary outcome measure</B>
<BR/>1. Mortality: death from AMI within 30 days.</P>
<P>
<B>Secondary outcome measures </B>
<BR/>1. Deterioration or improvement in symptoms of angina (such as chest pain, breathlessness, reduction in strength, etc).<BR/>2. Recurrent myocardial infarction.<BR/>3. Quality of life.<BR/>4. Readmission to hospital or use of revascularisation.<BR/>
<B>
<BR/>Adverse event outcome measures</B>
<BR/>Any adverse event as a result of treatment, including:</P>
<UL>
<LI>death;</LI>
<LI>life-threatening reactions; </LI>
<LI>toxic responses; </LI>
<LI>anaphylaxis; or </LI>
<LI>anything that resulted in discontinuation of treatment. </LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>
<B>Electronic searches</B>
<BR/>Searches were conducted to identify all published and unpublished randomised controlled trials (RCTs). Studies in any language were sought. Where necessary, non-English-language papers were translated so that they could be fully assessed for potential inclusion in the review.</P>
<P>Trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) on <I>The Cochrane Library</I> (Issue 4, 2006), MEDLINE (1966 to Dec., 2006), EMBASE (1980 - Dec., 2006) and the Chinese Biomedical Base, CBM (1982 - Dec., 2006). Search terms below were used for CENTRAL and adapted appropriately for other databases:</P>
<P>#1 DANSHEN <BR/>#2 (DAN next SHEN)<BR/>#3 SALVIA* <BR/>#4 SAGE<BR/>#5 (((#1 or #2) or #3) or #4)<BR/>#6 MYOCARDIAL-INFARCTION*:ME <BR/>#7 (MYOCARDIAL next INFARCT*) <BR/>#8 (ACUTE next CORONARY) <BR/>#9 (UNSTABLE near ANGINA) <BR/>#10 (HEART next ATTACK)<BR/>#11 (CORONARY near DISEASE)<BR/>#12 MYOCARDIAL-ISCHEMIA*:ME <BR/>#13 AMI <BR/>#14 (((((((#6 or #7) or #8) or #9) or #10) or #11) or #12) or #13) <BR/>#15 (#5 and #14)</P>
<P>
<B>Handsearches</B>
<BR/>We also searched the reference lists of relevant trials and identified reviews, and handsearched 75 Chinese traditional medicine Journals (listed in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>)</P>
<P>The International Standard Randomised Controlled Trial Number Register (ISRCTN) and ClinicalTrial.gov were also searched for ongoing trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>
<BR/>Trials selection</B> <BR/>TW and NJ scanned the results of the search relevant records were identified. Full articles for all potentially relevant trials were retrieved. Since all the publications were in Chinese, TW and NJ were able independently to interview by telephone many of the original authors to identify what method was used to generate the allocation sequence. TW selected the trials for inclusion. All identified reports were scrutinised to check for multiple publications of the same trials.</P>
<P>
<B>Quality assessment of trials</B>
<BR/>We assessed the methodological quality of each trial in terms of generation of allocation sequence, allocation concealment, blinding, and loss to follow up. For each trial, we classified each quality component as 'adequate', 'inadequate', 'unclear' or 'not used' according to the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). After including all eligible studies in the primary analysis, we conducted sensitivity analyses for each of the quality factors using the subgroups adequate, inadequate, or unclear. There were no recorded disagreements between the three authors' assessments.</P>
<P>
<B>Data extraction</B>
<BR/>We independently extracted data. A data abstraction form was specifically designed for this review, and included the following items:</P>
<UL>
<LI>General information: published/unpublished, title, authors, reference/source, contact address, country, urban/rural etc., language of publication, year of publication, duplicate publications, sponsor, setting.</LI>
<LI>Trial characteristics: design, duration of follow up, method of randomisation, allocation concealment, blinding (patients, people administering treatment, outcome assessors).</LI>
<LI>Intervention(s): intervention(s) (dose, route, timing), comparison intervention(s) (dose, route, timing), co-medication(s) (dose, route, timing).</LI>
<LI>Patients: inclusion and exclusion criteria, total number, and number in comparison groups, age, baseline characteristics, diagnostic criteria, similarity of groups at baseline (including any co-morbidity), assessment of compliance, withdrawals/losses to follow up (reasons/description), subgroups.</LI>
<LI>Outcomes: outcomes specified above, any other outcomes assessed, other events, length of follow up, quality of reporting of outcomes. </LI>
<LI>Results: for outcomes and times of assessment (including a measure of variation), where necessary these were converted to measures of effect specified below, and intention-to-treat analysis applied. </LI>
</UL>
<P>
<BR/>We also obtained more information e.g. on method of randomisation, allocation concealment from the original authors by telephone interview.</P>
<P>
<B>Data analysis</B>
<BR/>We analysed mortality using Review Manager (version 4.2.9) to perform a limited pooled analyses for two studies (<LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> and <LINK REF="STD-Chen-1984b" TYPE="STUDY">Chen 1984b</LINK>), because no heterogeneity was detected we used a fixed-effect model to pool the data. We conducted subgroup analysis based on gender, prospective versus retrospective studies, and different interventions, respectively, we did not combine data due to only one study included in these subgroups. The effects were presented as Peto odds ratio (Peto OR) together with 95% confidence intervals.<BR/>
</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<B>Studies identified</B>
<BR/>The initial search yielded 269 records. After scanning the title and abstract, 49 of these appeared to be comparative studies of danshen preparations. </P>
<P>
<B>Excluded studies</B>
<BR/>Of the 49 published articles initially identified, 19 articles were excluded as they were not randomised controlled comparisons (<LINK REF="STD-Chen-1996" TYPE="STUDY">Chen 1996</LINK>; <LINK REF="STD-Cui-2004" TYPE="STUDY">Cui 2004</LINK>; <LINK REF="STD-Dong-2002" TYPE="STUDY">Dong 2002</LINK>; <LINK REF="STD-Han-1992" TYPE="STUDY">Han 1992</LINK>; <LINK REF="STD-Li-2003" TYPE="STUDY">Li 2003</LINK>; <LINK REF="STD-Liang-2001" TYPE="STUDY">Liang 2001</LINK>; <LINK REF="STD-Liu-1998" TYPE="STUDY">Liu 1998</LINK>; <LINK REF="STD-Liu-2006b" TYPE="STUDY">Liu 2006b</LINK>; <LINK REF="STD-Luo-2001" TYPE="STUDY">Luo 2001</LINK>; <LINK REF="STD-Sun-1992" TYPE="STUDY">Sun 1992</LINK>; <LINK REF="STD-Sun-1997" TYPE="STUDY">Sun 1997</LINK>; <LINK REF="STD-Wang-1995" TYPE="STUDY">Wang 1995</LINK>; <LINK REF="STD-Wang-2000" TYPE="STUDY">Wang 2000</LINK>; <LINK REF="STD-Xu-2003" TYPE="STUDY">Xu 2003</LINK>; <LINK REF="STD-Yang-1997" TYPE="STUDY">Yang 1997</LINK>; <LINK REF="STD-Yuan-2003" TYPE="STUDY">Yuan 2003</LINK>; <LINK REF="STD-Zhang-1999" TYPE="STUDY">Zhang 1999</LINK>; <LINK REF="STD-Zhou-1996" TYPE="STUDY">Zhou 1996</LINK>; <LINK REF="STD-Zhu-2000" TYPE="STUDY">Zhu 2000</LINK>), seven articles were excluded as the outcome of interest was not reported (<LINK REF="STD-Cui-1983" TYPE="STUDY">Cui 1983</LINK>; <LINK REF="STD-Liang-1999" TYPE="STUDY">Liang 1999</LINK>, <LINK REF="STD-Shi-2000" TYPE="STUDY">Shi 2000</LINK>, <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>; <LINK REF="STD-Wu-2005" TYPE="STUDY">Wu 2005</LINK>; <LINK REF="STD-Zhang-2001" TYPE="STUDY">Zhang 2001</LINK>, <LINK REF="STD-Zhong-2000" TYPE="STUDY">Zhong 2000</LINK>); four studies were excluded one of which had an unclear description of interventions in the text (<LINK REF="STD-CYG-1981" TYPE="STUDY">CYG 1981</LINK>) and the remaining three were multiple versions of that study (<LINK REF="STD-Chen-1987" TYPE="STUDY">Chen 1987</LINK>; <LINK REF="STD-Chen-1988" TYPE="STUDY">Chen 1988</LINK>; <LINK REF="STD-GAM-1984" TYPE="STUDY">GAM 1984</LINK>); eight studies* were excluded as their aims of studies were assessment of other remedies for which danshen preparations served as control (<LINK REF="STD-Cha-1998" TYPE="STUDY">Cha 1998</LINK>; <LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-He-2000" TYPE="STUDY">He 2000</LINK>; <LINK REF="STD-Li-1995" TYPE="STUDY">Li 1995</LINK>; <LINK REF="STD-Tang-1999" TYPE="STUDY">Tang 1999</LINK>; <LINK REF="STD-Wang-1999" TYPE="STUDY">Wang 1999</LINK>; <LINK REF="STD-Xie-2001" TYPE="STUDY">Xie 2001</LINK>; <LINK REF="STD-Ye-2006" TYPE="STUDY">Ye 2006</LINK>), and five studies were excluded because they studied other remedies combined with danshen preparations (<LINK REF="STD-Deng-1998" TYPE="STUDY">Deng 1998</LINK>; <LINK REF="STD-Liang-2000" TYPE="STUDY">Liang 2000</LINK>; <LINK REF="STD-Qian-1996" TYPE="STUDY">Qian 1996</LINK>; <LINK REF="STD-Xu-2001" TYPE="STUDY">Xu 2001</LINK>; <LINK REF="STD-Zhou-1998" TYPE="STUDY">Zhou 1998</LINK>). Details of excluded studies are given in the table of excluded studies.</P>
<P>*In this group, six authors (<LINK REF="STD-Cha-1998" TYPE="STUDY">Cha 1998</LINK>; <LINK REF="STD-Chen-2004" TYPE="STUDY">Chen 2004</LINK>; <LINK REF="STD-He-2000" TYPE="STUDY">He 2000</LINK>; <LINK REF="STD-Li-1995" TYPE="STUDY">Li 1995</LINK>; <LINK REF="STD-Wang-1999" TYPE="STUDY">Wang 1999</LINK>; <LINK REF="STD-Ye-2006" TYPE="STUDY">Ye 2006</LINK>) were interviewed by telephone and were also excluded because the authors misunderstood the concept of randomisation.<BR/>
<BR/>
<B>Included studies</B>
<BR/>Only six studies (<LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK>; <LINK REF="STD-Chen-1984b" TYPE="STUDY">Chen 1984b</LINK>; <LINK REF="STD-Chen-2001" TYPE="STUDY">Chen 2001</LINK>; <LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK>; <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>; <LINK REF="STD-Zhang-1996" TYPE="STUDY">Zhang 1996</LINK>) were included in the review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>
<LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> was considered to be a quasi-RCT due to the fact that allocation was performed by odd or even number of admission order. Nonetheless it was our decision to include this trial as it represents the first clinical trial of danshen compounds for AMI supported by the Beijing government, and was carried out in several leading institutions. We included <LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> rather than <LINK REF="STD-CYG-1981" TYPE="STUDY">CYG 1981</LINK> because we noted that they were conducted concurrently in the same hospital and have the same project name, the sole differences being the authors' name and sample size, with <LINK REF="STD-CYG-1981" TYPE="STUDY">CYG 1981</LINK> reporting 276 cases and <LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> reporting 430 cases. From these findings we surmised that <LINK REF="STD-CYG-1981" TYPE="STUDY">CYG 1981</LINK> was included in <LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK>. </P>
<P>
<LINK REF="STD-Chen-2001" TYPE="STUDY">Chen 2001</LINK> was included as an RCT although there are still some uncertanties, for example, the authors were unable to remember the randomisation method, the paper was published 3 years after the study closed, and there were no usable data except the number of death. The reason for including this paper is pricipally to focus on discussing the shortcomings of trials of traditional Chinese medicine.<BR/>
<BR/>Only <LINK REF="STD-Chen-1984b" TYPE="STUDY">Chen 1984b</LINK> was considered an RCT (dependent on the description provided in the paper as "strictly random allocation") and as such was one of the most important studies of Danshen for AMI. We did not include other claimed RCTs or quasi-RCTs for the reason of poor methodology.</P>
<P>Although <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK> was not an RCT but rather a retrospective study, it was included because the randomisation to fufang danshen injection for treating AMI was felt to provide potentially important information, and the study was conducted in leading institutions under the support of the Shanghai government and with Huashan Hospital of Shanghai First University of Medical Sciences as a leader of this multicentre study. Patients were also treated in a standardised fashion and were monitored carefully, suggesting that the study might provide particularly worthwhile information. <BR/>
<B>
<BR/>
</B>
<LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK> and <LINK REF="STD-Zhang-1996" TYPE="STUDY">Zhang 1996</LINK> were included becuase they appeared (from the information provided) to be RCTs; unfortunately we were not able to contact the authors by telephone to clarify this issue.<BR/>
<B>
<BR/>
</B>All of the studies were published in Chinese.</P>
<P>A total of 2368 participants are included in the review. Numbers of participants in the individual studies ranged from 68 (<LINK REF="STD-Zhang-1996" TYPE="STUDY">Zhang 1996</LINK>) to 1350 (<LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>).</P>
<P>All of patients had been diagnosed with AMI by using the <LINK REF="REF-WHO-1979" TYPE="REFERENCE">WHO 1979</LINK> diagnosis criteria. Only one study (<LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK>) mentioned the traditional Chinese medicine (TCM) sign 'zheng' - 232 patients were recognised as 'qixu xueyu zheng' and some were 'yingxu xueyu' and 'xueyu'. However no numerical information was provided.<BR/>
<BR/>
<B>Interventions of included studies</B>
<BR/>Two studies (<LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> and <LINK REF="STD-Chen-1984b" TYPE="STUDY">Chen 1984b</LINK>) used the same interventions, where danshen was the principle ingredient of a 'kangxingeng heji' decoction and 'yiqi huoxue' injection. Within the first 6 hours of enrolment, AMI patients were treated with a 10 mL 'yiqi huoxue' injection together with a 250 mL infusion of 5% glucose infusion given by intravenous drip, which 1 week later was changed to taking 'kangxingeng heji' orally.</P>
<P>Both the 'quyu huatan xiezhu' and 'yiqi huoxue' formulations in the study by <LINK REF="STD-Chen-2001" TYPE="STUDY">Chen 2001</LINK> contain the basic elements danshen, chishao and honghua.</P>
<P>
<LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK> compared huangqi injection with danshen injection versus placebo, and shenmai injection with danshen injection versus placebo, respectively.</P>
<P>
<LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK> used intravenous danshen injection. <BR/>
<BR/>
<LINK REF="STD-Zhang-1996" TYPE="STUDY">Zhang 1996</LINK> used isosorbide dinitrate in the experimental group, and isosorbide dinitrate plus danshen injection in the control group.</P>
<P>See the Characteristics of included studies table for additional details.</P>
<P>
<B>Outcome measures of included studies</B>
<BR/>All studies reported mortality. <LINK REF="STD-Chen-2001" TYPE="STUDY">Chen 2001</LINK> listed frequency of angina pectoris, change of lung moist rales, and change of arrhythmia as outcomes, but there were no data that could be used for analysis. <LINK REF="STD-Zhang-1996" TYPE="STUDY">Zhang 1996</LINK> reported on improvement of heart function, but the data was unusable.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>All of the six included trials were of low quality (see Characteristics of included studies table). <BR/>
<B>
<BR/>Randomisation</B>
<BR/>Although all of the studies mentioned random allocation of participants, overall reporting of methods was poor. In <LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> it is mentioned that the patients with odd numbers were allocated to use 'yiqi huoxue' injection and to take 'kangxingeng heji' decoction, and the study was therefore considered as quasi-randomised. The authors of <LINK REF="STD-Chen-2001" TYPE="STUDY">Chen 2001</LINK> could not recall what method of randomisation was used. In <LINK REF="STD-Chen-1984b" TYPE="STUDY">Chen 1984b</LINK> it is stated that investigators "collected the strictly randomly allocated patients' data for analysis", and the study was therefore considered to be a valid RCT. The description in <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK> states that "patients were randomly allocated to danshen or control depending on whether they used danshen or not", and was considered to be a retrospective study. For <LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK> and <LINK REF="STD-Zhang-1996" TYPE="STUDY">Zhang 1996</LINK> attempts to contact the authors were unsuccessful. None of the studies concealed allocation.</P>
<P>
<B>Blinding</B>
<BR/>None of the studies used blinding.</P>
<P>
<B>Description of withdrawals and losses to follow up and intention-to-treat analysis</B>
<BR/>None of the included studies mentioned drop-outs or performed an intention-to-treat analysis. </P>
<P>
<B>Compliance assessment</B>
<BR/>None of the studies mentioned any methods of ensuring or assessing compliance.<BR/>
<B>
<BR/>Similarity of comparison groups at baseline</B>
<BR/>Comparisons of groups at baseline was mentioned in all of the included studies, and included age, sex, degree of heart dysfunction, infarct lacations, and disease duration, at time of entry into the study. However in some studies baselines were dissimilar, for example in <LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> there were 10 patients with the cardiogenic shock in the danshen group and 16 in the control group. In addition, 87 patients in the danshen group and 63 in the control group had heart failure. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>Mortality<BR/>
</B>The results for mortality are shown in comparison 01. The quasi-randomised study reported in <LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> demonstrated a significant difference favouring treatment with danshen versus controls (Peto OR 0.42, 95% CI 0.23 to 0.77). The study reported in <LINK REF="STD-Chen-1984b" TYPE="STUDY">Chen 1984b</LINK>, the sole investigation in this review that could confidently be considered an RCT, again showed fewer deaths in the group treated with danshen than the control group (8/112 versus 14/112, respectively), but in this case the difference was not statistically significant (Peto OR 0.55, 95% CI 0.23 to 1.32). However pooled analysis of these two studies using a fixed-effect model did yield a significant difference favouring danshen preparations (Peto OR 0.46, 95% CI 0.28 to 0.75). Although the number of studies is small and the rigour of conducting the trials somewhat uncertain, the results suggest that danshen therapy may reduce the death rate in AMI compared with conventional western therapy alone.<BR/>
<BR/>
<LINK REF="STD-Chen-2001" TYPE="STUDY">Chen 2001</LINK> concluded that the 'quyu huatan xiezhuo' formulation reduced both frequency of angina pectoris and onset of arrhythmia as compared with the 'yiqi huoxue' formulation (P &lt; 0.01, 0.05, respectively), but otherwise the author did not provide any useful data. There was no statistically significant difference between the two groups in mortality, with six deaths in a group of 61 patients in the 'quyu huatan xiezhuo' group, and four deaths among 60 patients in the 'yiqi huoxue' group (Peto OR 1.51, 95% CI 0.42 to 5.49).</P>
<P>The study described in <LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK> reported a single death in both the shenmai injection plus danshen injection group and the huangqi injection plus danshen groups, with eight deaths in each control group. There was a borderline statistically significant difference in the former (Peto OR 0.25, 95% CI 0.06 to 0.97), but not the latter (Peto OR 0.32, 95% CI 0.08 to 1.34).</P>
<P>In the retrospective study reported in <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>, an analysis of total mortality did not show a significant advantage for danshen (Peto OR 0.78, 95% CI 0.59 to 1.03; data not shown), whereas analysis according to gender showed an advantage for Danshen in males but not females (Peto OR 0.70, 95% CI 0.50 to 0.97 for men; 0.78, 95% CI 0.59 to 1.03 for women). However these values lie very close to one another and are of doubtful clinical significance.<BR/>
<BR/>The study reported in <LINK REF="STD-Zhang-1996" TYPE="STUDY">Zhang 1996</LINK> cites the number of deaths in the study groups in the results section, although mortality was not listed as an outcome. Deaths in the isosorbide dinitrate plus danshen group numbered six of 24 patients, and in the isosorbide dinitrate group two of 24 patients, a non-significant difference (Peto OR 3.05, 95% CI 0.71 to 13.21).</P>
<P>In summary, this group of studies, which are often questionable in both design and interpretation, also collectively do not offer strong support for the use of danshen in treating AMI.<BR/>
<BR/>
<B>Rate of severe arrhythmia</B>
<BR/>The study reported in <LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK> indicated that the use of both fufang danshen injection plus huangqi injection and fufang danshen injection plus shenmai injection significantly reduced the rate of severe arrhythmia (Peto OR 0.28, 95% CI 0.12 to 0.67, and Peto OR 0.42, 95% CI 0.20 to 0.91, respectively).<BR/>
<BR/>
<B>Rate of heart failure</B>
<BR/>The study reported in <LINK REF="STD-Li-2004" TYPE="STUDY">Li 2004</LINK> indicated that the use of fufang danshen injection plus huangqi injection failed to reduce the rate of heart failure (Peto OR 0.49, 95% CI 0.13 to 1.89), whereas use of fufang danshen injection with shenmai injection did show a significant advantage (Peto OR 0.16, 95% CI 0.04 to 0.65).<BR/>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>We found that studies of danshen preparations for AMI were inadequate to provide reliable estimates on the effects, due to poor study design and methodological quality of the research protocols. The following need to be considered:</P>
<P>1. All of the studies located were Chinese language publications, facilitating our telephone contact with many of the trial authors about the method of randomisation they used. Although a large number of the trials claimed to be RCTs, we found that few of the authors had described the concept of randomisation correctly. In addition to this, some of the studies were conducted several years prior to publication, and the trial authors in some instances seemed unfamiliar with the details of the methodology they employed. Even in some leading institutions such as those connected with the studies reported in <LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> and <LINK REF="STD-Wang-1994" TYPE="STUDY">Wang 1994</LINK>, the description of the randomisation process sometimes appeared flawed. None of the trials used concealment of allocation. These two limitations may have resulted in a high risk of selection bias.</P>
<P>2. None of studies mentioned ethical issues or whether the participants gave informed consent.</P>
<P>3. We found that in all of the trials using danshen, the comparator treatment or 'basal or routine treatment' was often sub-optimal with some patients receiving only nitrates, and not low molecular weight heparin or other effective remedies (<LINK REF="REF-ICSI-2005" TYPE="REFERENCE">ICSI 2005</LINK>). Consequently, danshen may have shown exaggerated beneficial effects in such trials.</P>
<P>4. A large number of the trials used self-prepared formulation or hospital-made preparations for treating AMI. Although Chinese herbal medicine as a treatment for diseases and their method of manufacture are widely accepted in China, many of the constituents of the pharmacologically prepared drugs used in trials cannot be clearly specified. This is in marked contrast to pharmacological agents used in western medicine, in which the chemical constituents, their quantities, the percentage of any impurities or contaminants are precisely known and the variation between different production batches is kept within specified limits. Variation between formulations and batches of treatments are inevitable consequences of traditional Chinese medicine, though the Chinese government does specify the acceptable limits of variation. However this variation is a factor that may contribute to any heterogeneity between different study results.</P>
<P>One must accept the fact that the overall treatment concept for traditional Chinese medicine is different from that used in Western medicine. Nonetheless, when a study uses a self-prepared herbal formulation, the quality of herbs and methods of preparation should be stated in detail, in order to achieve consistent effects.</P>
<P>5. It is noteworthy that in <LINK REF="STD-Chen-2001" TYPE="STUDY">Chen 2001</LINK> an attempt was made to explore the effects of different Danshen compounds for AMI patients with different types of the traditional Chinese medicine sign 'zheng'. Sixty-one AMI patients were in the 'quyu huatan xiezhuo' group, of these nine were 'qixu xueyu zheng', three with both 'qi and yin xu zheng', four with 'tanshi zhuci zheng'and 45 with 'tanyu huzhu zheng' (means both 'tan and yu' stasis and interacted each other). Of 60 in the 'yiqi huoxue' group, six were with "qixu xueyu zheng', three with both 'qi and yin xu zheng', three with 'tanshi zhucu zheng' and 48 with 'tanyu huzhu zheng'. The results appeared to suggest that 'quyu huatan xiezhuo' formulation is superior to 'yiqi huoxue' formulation in improving heart function and heart failure, and reducing angina attack and arrhythmia. This result alludes to that (1) traditional Chinese medicine preparations should be used according to the traditional Chinese medicine signs 'zheng' of patients strictly; and (2) most AMI patients are with 'tanyu huzhu zheng'. Regrettably the authors did not perform a stratification analysis by 'zheng'. There is a need to conduct more and better designed studies to test whether use of danshen preparations for treating AMI is dependent on the traditional Chinese medicine 'zheng' or not.</P>
<P>6. We also noted that if danshen was studied as the experimental drug, it tended to show a better result than the controls, and that conversely when danshen was an agent in the control group, the experimental drug tended to be superior to danshen. For example in <LINK REF="STD-Chen-1984a" TYPE="STUDY">Chen 1984a</LINK> and <LINK REF="STD-Chen-1984b" TYPE="STUDY">Chen 1984b</LINK> as well as in other excluded studies such as <LINK REF="STD-Han-1992" TYPE="STUDY">Han 1992</LINK> and <LINK REF="STD-Liang-2001" TYPE="STUDY">Liang 2001</LINK> in which danshen preparations was used as the experimental intervention, positive effects of danshen were noted. In contrast, in <LINK REF="STD-Zhang-1996" TYPE="STUDY">Zhang 1996</LINK>, in which isosorbide dinitrate was used as the experimental drug and the control group was given isosorbide dinitrate plus danshen injection, there was a trend for the former treatment to be superior to the latter treatment, albeit not significantly so. However these somewhat inconsistent results may result at least in part from selection bias or detection bias, and possibly even conflict of interest should be considered.</P>
<P>7. We did not find any studies that reported calculation of sample size requirements. This may explain the conduct of smaller studies with low power to detect clinically important differences. Any future studies should be adequately powered. <BR/>
</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>From the six studies included in this review, it is concluded that, although danshen compound may possibly have beneficial effects on AMI mortality compared to routine treatments, the evidence must be considered inconclusive. This is because of the small number of available studies which were of poor quality. In addition, the safety of danshen preparation is unproven because of the lack of toxicological evidence, although adverse events have only rarely been reported.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further research should consider the following points:<BR/>1. The design and performance of trials should be greatly improved, and include adequate methods for randomisation. Attention should be given to the generation of allocation sequences, insuring that the person who generated the allocation sequence is not involved in patient recruitment, etc.<BR/>2. Reconciling the method of Danshen treatment with the traditional Chinese medicine 'zheng' of AMI patients, assuring that the control traditional Chinese medicine formulation should suit the type of 'zheng', and ensuring that the traditional Chinese medicine outcome is an endpoint outcome rather than simply an intermediate outcome. <BR/>3. If an active drug is used as control, its effect should be supported by reliable evidence.<BR/>4. Sample size calculations should be made, and should match the power requirement of study type. It should be specified whether the objective is to demonstrate equivalence, non-inferiority, or superiority.</P>
<P>The reporting of the trials should focus in detail on how to achieve allocation concealment and blinding of participants, investigators and outcome assessors, according to CONSORT for traditional Chinese medicine (<LINK REF="REF-Wu-2007" TYPE="REFERENCE">Wu 2007</LINK>) and CONSORT (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). In particular the statement should include:<BR/>1. Description of the components of the formulations, who provided or prepared (made) the medicine (including tablet, decoction, injection, or other forms of traditional Chinese medicine).<BR/>2. If a decoction was used as the intervention, a detailed statement of the quality of herbs, methods of preparation, and means of assuring that blinding is maintained.<BR/>3. The traditional Chinese medicine signs should be described and defined in detail, for example, what kinds of 'zheng' of participants were included? What diagnosis standard was used?<BR/>4. Assurance that those who evaluate traditional Chinese medicine signs for assessment of effects is done in a manner that preserves blinding.<BR/>5. Assurance that the quality assessment of traditional Chinese medicine outcomes is done in a way that preserves blinding.<BR/>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>This publication was made possible in part by Grant Number 1 R24 AT001293-01 from the National Center for Complementary and Alternative Medicine (NCCAM). The contents of this review are solely the responsibility of the authors and do not necessarily represent the official views of the NCCAM, or the National Institutes of Health.</P>
<P>We thank the Cochrane Heart Group editorial board for their kind help for writing this review.</P>
<P>We thank Zhou Likun, Duan Xin, Qiao Jieqi, Chen Xiaoyan, Zhen Jie, Wang Qin for their contribution to the handsearch.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Taixiang, Wu<BR/>Protocol development, searching for trials, quality assessment of trials, data extraction, data analysis, telephone interview the original authors, review development.<BR/>Juan, Ni<BR/>Protocol development, searching for trials, quality assessment of trials, data extraction, telephone interview the original author..<BR/>Jiafu, Wei<BR/>Searching for trials, quality assessment of trials, data extraction.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2013-03-04 10:43:19 +0000" MODIFIED_BY="[Empty name]">
<P>Authors are not able to update the review.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1984a" NAME="Chen 1984a" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chen DQ, Wong XZ, Zhao LY, Li MQ</AU>
<TI>Yiqi Huoxue mixture with Western medicine compared to Western medicine alone in the treatment of 430 patients with AMI and an animal research</TI>
<SO>Journal of Medical Research</SO>
<YR>1984</YR>
<NO>9</NO>
<PG>20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1984b" NAME="Chen 1984b" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen KJ, Qian ZH, Dong QZ, Tu XH, Tao SY, Tao SQ</AU>
<TI>A randomised controlled trial of Yiqi Huoxue Zhusheyie injection in the treatment of 224 patients with AMI</TI>
<SO>Chinese Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>1984</YR>
<VL>4</VL>
<NO>7</NO>
<PG>416</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2001" NAME="Chen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen KY, Wu DL, Chen XL, Wang XF, Shi DZ</AU>
<TI>A clinical observation for the effect of "Quyu Huatan Xiezhuo" formulation in the treatment of patients with AMI</TI>
<SO>China Journal of Traditional Chinese Medicine</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>5</NO>
<PG>34-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2004" NAME="Li 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Y, Chen LX, Liu QQ</AU>
<TI>Huangqi, Shenmai injection combined with Fufang danshen injection in the treatment of 99 patients with AMI</TI>
<SO>Journal of Traditional Chinese Medicine</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>1</NO>
<PG>45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1994" NAME="Wang 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang SY, Dai RH, Fan WF</AU>
<TI>The effect of "Dan Shen" injection for acute myocardial infection</TI>
<SO>Journal of Traditional Chinese Medicine</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>1</NO>
<PG>29-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1996" NAME="Zhang 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Zhang KL</AU>
<TI>Influence of isosorbide dinitrate for heart function of AMI patients</TI>
<SO>Qingdao Medical Journal</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>1</NO>
<PG>12-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Cha-1998" NAME="Cha 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cha YX</AU>
<TI>Observation for the effect of Bothropsatrox antithrombusase in the treatment of acute myocardial infarction</TI>
<SO>Jiaotong Medicine</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>1</NO>
<PG>30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1987" NAME="Chen 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen DQ, Weng XZ, Zhao LY</AU>
<TI>Integrated TCM and Western medicine compared to Western medicine alone in the treatment of 233 patients with AMI complicated with arrhythmia</TI>
<SO>Shanxi TCM</SO>
<YR>1987</YR>
<VL>3</VL>
<NO>2</NO>
<PG>19-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1988" NAME="Chen 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen DQ</AU>
<TI>Comparing TCM with Western medicine in the treatment of 181 patients with AMI complicated with heart failure</TI>
<SO>Journal of Practical Internal TCM</SO>
<YR>1988</YR>
<VL>2</VL>
<NO>1</NO>
<PG>17-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1996" NAME="Chen 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen HT</AU>
<TI>Observation for effects of middle and low does urokinase in the treatment of 43 senior patients with AMI</TI>
<SO>Chinese Journal of Clinical Pharmacology and Therapeutic</SO>
<YR>1996</YR>
<VL>1</VL>
<NO>1</NO>
<PG>41-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2004" NAME="Chen 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen SQ, Jiang H</AU>
<TI>Bothropsatrox antithrombusase in the treatment of patients with AMI</TI>
<SO>Journal of Microcycology</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>3</NO>
<PG>87 and 90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Cui-1983" NAME="Cui 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cui ZC, Li QL, Yao JN, Wang M, Gu FS, Su CL, et al</AU>
<TI>The effect of blood serum enzyme, platelet congregate activity and blood rheology in "Kangxingeng Heji" for acute myocardial infarction</TI>
<SO>Integrate Chinese Traditional and Western Medicine Journal</SO>
<YR>1983</YR>
<VL>3</VL>
<NO>5</NO>
<PG>268-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cui-2004" NAME="Cui 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cui CX, Wei XL</AU>
<TI>Obervation for the effects of integrated traditional Chinese and western medicine in the treatment of patients with AMI</TI>
<SO>Liaoning Journal of TCM</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>10</NO>
<PG>868-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CYG-1981" NAME="CYG 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beijing Chao-yang Hospital and TCM Institute Guang-an Men Hospital coronary heart disease group</AU>
<TI>The primary observation for comparing of integrated Chinese traditional medicine and Western medicine to western medicine along in the treatment of 276 patients with acute myocardial infection</TI>
<SO>Chinese Journal of Integrated Traditonal Chinese and Western Medicine</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>1</NO>
<PG>10-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deng-1998" NAME="Deng 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deng XM, Tang AH</AU>
<TI>Observation for the effect of integrated traditional Chinese and western medicine in the treatment of 36 patients with AMI</TI>
<SO>Jounal of Guangxi College of TCM</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>2</NO>
<PG>29-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dong-2002" NAME="Dong 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dong SP, Shen J</AU>
<TI>The efficacy of "Huangqi", "Dan Shen" injection for acute myocardial infarction</TI>
<SO>Taishan Waisheng</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>3</NO>
<PG>36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GAM-1984" NAME="GAM 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guang Anmen hospital , Chao Yang hospital, Beijing Red Cross Hospital heart group</AU>
<TI>"Yiqi Huoxue Heji" for acute myocardial infarction</TI>
<SO>Journal of Traditional Chinese Medicine</SO>
<YR>1984</YR>
<NO>12</NO>
<PG>22-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-1992" NAME="Han 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han GZ</AU>
<TI>Integrated traditional Chinese medicine with Western medicine in the treatment of 88 patients with acute myocardial infarction</TI>
<SO>Shanxi TCM</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>4</NO>
<PG>152-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2000" NAME="He 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He WG, Fang D, Li YJ, Liang FQ</AU>
<TI>Observation on the effect of defirase for acute myocardial infarction</TI>
<SO>Journal of Youjiang Medical College for Nationalities</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>5</NO>
<PG>715-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1995" NAME="Li 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li ZS</AU>
<TI>Bothropsatrox antithrombusase in the treatment of patients with AMI</TI>
<SO>Shandon Medicine</SO>
<YR>1995</YR>
<VL>35</VL>
<NO>9</NO>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Li-2003" NAME="Li 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li J, Jiang T</AU>
<TI>The effect of compound Danshen pill in the treatment of patients with acute myocardial infarction left ventrical reconstruction</TI>
<SO>Tian Jin Pharmacy</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>1</NO>
<PG>36-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Liang-1999" NAME="Liang 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang TJ, Gao SZ, Wang AW</AU>
<TI>The effect of blood serum muscle-calcium protein in "Dan Shen" compound pill for acute myocardial infarction patients</TI>
<SO>Li Shizhen Medicine and Materia Medica Research</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>2</NO>
<PG>90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2000" NAME="Liang 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang J, Li QR, Wang LM</AU>
<TI>Comparing the effect of thrombolytic combined with TCM in the treatment of 32 patients with AMI</TI>
<SO>Anthology of Medicine</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>6</NO>
<PG>868-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2001" NAME="Liang 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang JL, Sun ZX, Qu F</AU>
<TI>A clinical observation on integrated traditional Chinese and western medicine in the treatment of patients with AMI</TI>
<SO>Journal of Tianjin College of Traditional Chinese Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>3</NO>
<PG>24-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1998" NAME="Liu 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu LS, Wang W, Fang WQ, Pan XW, Huang P, Ma FZ, et al</AU>
<TI>Effects of captopril combined with other medicines on clinical cardiovascular events among 14962 patients with acute myocardial infarction - Chinese Cardiac Study (CCS-1) subgroup report</TI>
<SO>Chinese Journal of Hypertension</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>2</NO>
<PG>157-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006b" NAME="Liu 2006b" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu DF, Liu L</AU>
<TI>Xiaogentang decoction with western medicine in the treatment of 30 patients with AMI</TI>
<SO>Shanxi TCM</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>7</NO>
<PG>786-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2001" NAME="Luo 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo B</AU>
<TI>Integrate traditional Chinese and western medicine for acute myocardial infarction complicated with heart failure</TI>
<SO>Hubei Journal of TCM</SO>
<YR>2001</YR>
<VL>23</VL>
<NO>4</NO>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qian-1996" NAME="Qian 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qian KY, Tian ZZ</AU>
<TI>Integrated TCM and western medicine in the treatment of 50 patients with AMI</TI>
<SO>Chinese Journal of Integrated Traditional Chinese and Western Medicine</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>5</NO>
<PG>308-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Shi-2000" NAME="Shi 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi XY, Xia ZY, Fang JG, Gu JZ, Wu LW, Yu JP</AU>
<TI>Effects of salvia miltiorrhiza compound injection on serum endothelin, prostaglandin I2/thromboxane A2 atio alteration following myocardial ischemia-reperfusion in patients undergoing intracardiac surgery</TI>
<SO>Chinese Journal of Integrate Chinese Traditional and Western Medicine</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>12</NO>
<PG>896-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-1992" NAME="Sun 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun JQ, Wang SK, Cheng JL, Wu ST, Wang XJ, Huang JH</AU>
<TI>Observation for effect of integrated traditional Chinese medicine with western medicine in the treatment of 37 patients with acute myocardial infection</TI>
<SO>Acta Chinese Medicine and Pharmacology</SO>
<YR>1992</YR>
<NO>1</NO>
<PG>34-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-1997" NAME="Sun 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun WF, Wang LL, Wang XM, Wang GL, Yin ZY</AU>
<TI>Integrated traditional Chinese and western medicine for acute myocardial infarction complicated with heart failure</TI>
<SO>Acta Chinese Medicine and Pharmacology</SO>
<YR>1997</YR>
<NO>2</NO>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-1999" NAME="Tang 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang CS</AU>
<TI>Clinical observation on the effect of Shanmai injection in the treatment of 60 patients with AMI</TI>
<SO>Hainan Medicine</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>6</NO>
<PG>54-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1995" NAME="Wang 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang JK</AU>
<TI>Observation for the clinical effect of Danshen compound in the treatment of 51 patients with acute myocardial infarction in an hour</TI>
<SO>Ge Jiu Science and Technology</SO>
<YR>1995</YR>
<NO>1</NO>
<PG>18-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1999" NAME="Wang 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang ZF, Shu HQ, Wang LN</AU>
<TI>Bothropsatrox antithrombusase in the treatment of 80 patients with AMI</TI>
<SO>Journal of Snake</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>4</NO>
<PG>63-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000" NAME="Wang 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Q, Yin XZ, Zhao RJ, Chang YP, Jiang ZP</AU>
<TI>Observation for the effects of Shanmai injection combined with Danshen powder injection in the treatment of patients with AMI with conduction block</TI>
<SO>Chinese Journal of TCM Emergency</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>6</NO>
<PG>261</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wang-2003" NAME="Wang 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang YS, Zhang S, Zhang D, Liu ZM</AU>
<TI>Protective effects of Shenmai and salvia Miltiorrhiza injection on ischemia and reperfusion myocardium in acute myocardial infarction patients</TI>
<SO>Chin J Crit Care Med</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>12</NO>
<PG>834-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2005" NAME="Wu 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu ZD, Guo XQ</AU>
<TI>Point injecting by Danshan injection for the hiccup after AMI</TI>
<SO>Guangdo Medicine</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>3</NO>
<PG>407-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2001" NAME="Xie 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie J, Li SQ, Zhao L</AU>
<TI>A clinical study of Dan Ao in the treatment of patients with AMI</TI>
<SO>Clinical Medicine</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>10</NO>
<PG>50-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2001" NAME="Xu 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Xu GH, Zhang XS, Huang ZX, Liu M</AU>
<TI>Observation for the effect of "Wutou Cishitang" decoction with "Dan Shen" injection in the treatment of acute myocardial infarction</TI>
<SO>New Chinese Medicine</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>9</NO>
<PG>30-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Xu-2003" NAME="Xu 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu XL, Wang BW</AU>
<TI>The effect of re-open rate with integrated Chinese traditional and western medicine for acute myocardial infarction</TI>
<SO>Chinese Journal of Practical Medicine</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>9</NO>
<PG>831-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-1997" NAME="Yang 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang YS, Zhang H, Zhang RJ, Wu XX</AU>
<TI>Observation for effect of integrated traditional Chinese medicine in the treatment of patients with acute myocardial infection</TI>
<SO>Tianjin Journal of TCM</SO>
<YR>1997</YR>
<VL>14</VL>
<NO>3</NO>
<PG>105-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ye-2006" NAME="Ye 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ye ZB</AU>
<TI>Bothropsatrox antithrombusase in the treatment of AMI</TI>
<SO>Chinese Medical Journal of Metallurgical Industry</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>2</NO>
<PG>162-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Yuan-2003" NAME="Yuan 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan ZM, Di RA, Zhao WY</AU>
<TI>"Dan Shen" injection with vienal dissolve embolism therapy for 46 patients with acute myocardial infection</TI>
<SO>Shanxi TCM</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>2</NO>
<PG>107-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1999" NAME="Zhang 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang DJ, Tang BX, Xu NT, Yang RP, Chang BX, Yan JL</AU>
<TI>Comparing integrated Chinese traditonal medicine to western medicine in 52 patients with acute myocardial infarction</TI>
<SO>Clinical Report</SO>
<YR>1999</YR>
<NO>5</NO>
<PG>16-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Zhang-2001" NAME="Zhang 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang YH</AU>
<TI>The effect of "Dan Shen" compound pill for the QT period disperse degree of acute myocardial infarction</TI>
<SO>Chinese Journal of Cardiovasc Rehabil Medicine</SO>
<YR>201</YR>
<VL>10</VL>
<NO>4</NO>
<PG>371-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Zhong-2000" NAME="Zhong 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong JB, Zhang JC, Miao Y, Tu XH, Qian HY, Xu MY</AU>
<TI>Observation on the therapeutic effect of " Phlegm-Stasis Eliminating Formula" in the treatment of acute myocardial infarction in early stage</TI>
<SO>Shanghai Journal of Traditional Chinese Medicine</SO>
<YR>2000</YR>
<VL>34</VL>
<NO>4</NO>
<PG>26-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISSN:1007-1334"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-1996" NAME="Zhou 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhou YH</AU>
<TI>Observation for the effect of polarization fluid combined with Mg, low-melocule dextran and "Dan Shen" compound injection for acute myocardial infarction</TI>
<SO>Journal of Emergency in Traditional Chinese and Westen Medicine</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>9</NO>
<PG>397-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-1998" NAME="Zhou 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Y, You WQ, Xiou H</AU>
<TI>Danshen and Huangqi injection in the treatment of 50 patients with AMI complicated with heart function deficiency</TI>
<SO>Information on Traditional Chinese Medicine</SO>
<YR>1998</YR>
<NO>2</NO>
<PG>24-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2000" NAME="Zhu 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu MJ, Shi XQ, Fan HL</AU>
<TI>Clinical observation for integrated traditional Chinese medicine and Western medicine in the treatment of 58 patients with AMI</TI>
<SO>Journal of Shanxi TCM</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>4</NO>
<PG>30-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bensky-1987" NAME="Bensky 1987" TYPE="BOOK">
<AU>Bensky D, Gamble A</AU>
<SO>Chinese Herbal Medicine: Materia Medica</SO>
<YR>1987</YR>
<PG>384</PG>
<PB>Eastland Press</PB>
<CY>Seattle</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BHMA-1983" NAME="BHMA 1983" TYPE="BOOK">
<AU>British Herbal Medicine Association</AU>
<SO>British Herbal Pharmacopoeia</SO>
<YR>1983</YR>
<PB>BHMA</PB>
<CY>Bournemouth</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brooks-2001" NAME="Brooks 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brooks N</AU>
<TI>Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit</TI>
<SO>Heart</SO>
<YR>2001</YR>
<VL>85</VL>
<NO>2</NO>
<PG>133-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burton-1996" NAME="Burton 1996" TYPE="BOOK_SECTION">
<AU>Burton E.Sobel</AU>
<TI>Acute myocardial infarction</TI>
<SO>Cecil's Textbook of Medicine</SO>
<YR>1996</YR>
<EN>20th</EN>
<ED>Bennet C J, Plum F</ED>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="o-7216-3561-x"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chan-2001" NAME="Chan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Chan TY</AU>
<TI>Interaction between warfarin and danshen (Salvia miltiorrhiza)</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2001</YR>
<VL>35</VL>
<NO>4</NO>
<PG>501-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garjani-2000" NAME="Garjani 2000" TYPE="JOURNAL_ARTICLE">
<AU>Garjani A, Nazemiyeh H, Maleki N, Valizadeh H</AU>
<TI>Effects of extracts from flowering tops of Crataegus meyeri A. Pojark. on ischaemic arrhythmias in anaesthetized rats</TI>
<SO>Phytotherapy Research</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>6</NO>
<PG>428-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-He-2006" NAME="He 2006" TYPE="JOURNAL_ARTICLE">
<AU>He Q</AU>
<TI>Analysis for 25 patients with side effect caused by Fufang Danshen injection</TI>
<SO>Clinical Medicine</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>12</NO>
<PG>91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herlitz-1989" NAME="Herlitz 1989" TYPE="JOURNAL_ARTICLE">
<AU>Herlitz J, Blohm M, Hartford M, Hjalmarsson A, Holmberg S, Karlson BW</AU>
<TI>Delay time in suspected acute myocardial infarction and the importance of its modification</TI>
<SO>Clinical Cardiology</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>7</NO>
<PG>370-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" NAME="Higgins 2006" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]</TI>
<SO>www.cochrane.org/resources/handbook/hbook.htm</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICSI-2005" NAME="ICSI 2005" TYPE="OTHER">
<AU>Institute for Clinical Systems Improvement (ICSI)</AU>
<TI>Diagnosis and treatment of chest pain and acute coronary syndrome (ACS)</TI>
<SO>http://www.guideline.gov/summary/summary.aspx?doc_id=8362&amp;nbr=4683 [accessed 15 Jan 2006]</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2006a" NAME="Liu 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Song Y, Li M</AU>
<TI>Danshen's pharmaceutic function and its clinical use</TI>
<SO>Chinese Journal of Misdiagnosis</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>24</NO>
<PG>4732-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2006" NAME="Lu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lu JJ, Chen YH</AU>
<TI>Two cases of anaphylaxic shock caused by Fufang Danshen injection intravenous drip</TI>
<SO>Clinical Misdiagnosis &amp; Mistherapy</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>7</NO>
<PG>90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCann-2001" NAME="McCann 2001" TYPE="JOURNAL_ARTICLE">
<AU>MacIntyre K, Stewart S, Capewell S, Chalmers JW, Pell JP, Boyd J, et al</AU>
<TI>A population-based study of 201,114 men and women following a first acute myocardial infarction</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>3</NO>
<PG>729-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>15</NO>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MVS-2002" NAME="MVS 2002" TYPE="OTHER">
<AU>MVS</AU>
<TI>MVS Pathophysiology: Myocardial Infarction</TI>
<SO>http://sprojects.mmip.mcgill.ca/mvs/PATHOS/MI.HTM#anchor175396</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Negard-1996" NAME="Negard 1996" TYPE="JOURNAL_ARTICLE">
<AU>Nagai M, Noguchi M, Iizuka T, Otani K, Kamata K</AU>
<TI>Vasodilator effects of des(alpha-carboxy-3,4- dihydroxyphenethyl)lithospermic acid (8-epiblechnic acid), a derivative of lithospermic acids in salviae miltiorrhizae radix</TI>
<SO>Biological and Pharmaceutical Bulletin</SO>
<YR>1996</YR>
<VL>19</VL>
<PG>228-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHLBI-1992" NAME="NHLBI 1992" TYPE="BOOK">
<AU>National Heart Lung and Blood Institute</AU>
<SO>Morbidity and Mortality: Chartbook on Cardiovascular, Lung, and Blood Diseases</SO>
<YR>May 1992</YR>
<PB>NHLBI</PB>
<CY>Bethesda, Md, US</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sang-1979" NAME="Sang 1979" TYPE="JOURNAL_ARTICLE">
<AU>Sang GW</AU>
<TI>The investigation of pharmacological effect of Dan Shen and Dan Shen compound</TI>
<SO>ZheJiang medicine</SO>
<YR>1979</YR>
<VL>1</VL>
<NO>1</NO>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-1996" NAME="Wang 1996" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Pang J, Shan C, Yang S, Zheng Y</AU>
<TI>Effect of danshen injection on pulmonary thromboembolism and platelet free radical levels in mice</TI>
<SO>Zhongguo Zhong Yao Za Zhi</SO>
<YR>1996</YR>
<VL>21</VL>
<PG>558-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1979" NAME="WHO 1979" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature</TI>
<SO>Circulation</SO>
<YR>1979</YR>
<VL>59</VL>
<NO>3</NO>
<PG>607-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-1998" NAME="Wu 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wu YJ, Hong CY, Lin SJ, Wu P, Shiao MS</AU>
<TI>Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza</TI>
<SO>Arteriosclerosis, Thrombosis &amp; Vascular Biology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>3</NO>
<PG>481-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2007" NAME="Wu 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wu TX, Li YP, Bian ZX, Li TQ, Li J, Dagenais S, et al</AU>
<TI>Consolidated Standards for Reporting Trials of Traditional Chinese Medicine (CONSORT for TCM)</TI>
<SO>Journal of Evidence-Based Medicine</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>8</NO>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xu-2006" NAME="Xu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Xu MG, Luo YH</AU>
<TI>Analysis for side effects of 98 patients treated by Fufang Danshen injection</TI>
<SO>Journal of Hubei Institute for Nationalities. Medical Edition</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>3</NO>
<PG>1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhen-1997" NAME="Zhen 1997" TYPE="BOOK_SECTION">
<AU>Zhen HZ, Dong ZH, She J</AU>
<TI>Danshen</TI>
<SO>Modern Study of Traditional Chinese Medicine</SO>
<YR>1997</YR>
<VL>2</VL>
<PG>1093-1193</PG>
<PB>Xue Yuan Publish House</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhou-1991" NAME="Zhou 1991" TYPE="JOURNAL_ARTICLE">
<AU>W Zhou</AU>
<TI>Protective effect of Dan Shen on myocardial ischemia and reperfusion: An isolated rat heart study</TI>
<SO>American Journal of Chinese Medicine</SO>
<YR>1990</YR>
<VL>18</VL>
<PG>19-21</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Chen-1984a">
<CHAR_METHODS>
<P>"Random allocation" was mentioned, but the method of randomisation unclear. In CYG 1981, the randomisation was described as "patients with odds numbers were allocated to TCM with western medicine group". Hence, we considered it a quasi-RCT. No blinding, baseline similar (P&gt;0.05)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>430 participants diagnosed by WHO 1979 criteria of AMI. <BR/>Treatment group: 215 patients, M/F=150/65, age: 3 patients &lt; 40 years; 45 patients = 41-50 years; 78 patients = 51-60 years; 57 patients = 61-70 years; 32 patients &gt; 70 years. <BR/>Control group: 215 patients, M/F=133/82, age: 9 patients &lt; 40 years; 54 patients = 41-50 years; 61 patients = 51-60 years; 49 patients = 61-70 years; 42 patients &gt;70 years. TCM signs were used to sort the type of patients. Of these patients, 232 were 'qixu xueyu zheng', some were 'yingxu xueyu' and 'xueyu', but the numbers were not mentioned.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>'Yiqi huoxue heji" decoction was taken orally, and water extraction of huangqi, danshen and huangjin named as 'yiqi' injection, water extraction of danshen, cishao and yujin called 'huoxue' injection were intravenous drip in the integrated TCM group. <BR/>Both integrated TCM (group A) and western medicine (group B) groups were given routine treatment: monitor, isosorbide dinitrate 0.1g, dipyridamole 0.1g 3 times per day. No longer than six hours after enrolment, the patients in integrated TCM group were given both 'yiqi' injection and 'huoxue' injection by intravenous drip, and oral 'yiqi huoxue heji' decoction for 8 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality: 14 deaths in the integrated TCM and western medicine group during the trial, while 32 patients died in the control group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>This was the second version of CYG 1981. This was the first ever study of danshen in the treatment of AMI. We decided to include this trial because of its position on the danshen therapeutic research for AMI although its randomisation may not be exactly correct that can be judged from its baseline not similar, for example, 10 patients complicated with the cardiogenic shock in the A group and 16 in the B group at the begining of treatment; 87 patients in the A group and 63 in control group complicated with heart failure; etc. In the other versions of this study, for example, Chen 1987 and Chen 1988, the method of randomisation was described as that "the odd number patients" were allocated to integrade TCM and western group, and the even numbers were allocated to the western medicine group. The number of patients in two groups were exactly equel: 215/215. So, this study was not considered as a RCT but a quasi-RCT, and there was a high potential risk of selection bias.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chen-1984b">
<CHAR_METHODS>
<P>It was described that the participants with AMI where allocated into two arms by critical randomisation. But the method was not mentioned. No blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>224 AMI patients diagnosed by WHO criteria and no longer than 72 hours after onset were included and equally allocated to two groups. Of these patients, M/F 159/65; 121 patients older than 60 years old; 168 patients with infarction at anterior or/and antesepterior or/and inferior myocardial infarction; 119 patients complicated with hypertension, some with cerebral disease or/and diabetes. There was no any significant difference between two groups on baseline.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>'Yiqi huoxue' injection was the water abstration of huangqi, danshen, huanjin, chishao, yujin. Routine treatment (western medicine) was given in both two groups, and the 'yiqi huoxue' injection was used by intravenous drip in a does of 10 mL in 250 mL 5% glucose infusion within 6 hours after enrolment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Mortality: 8 participants died in integrated TCM and western group and 14 in control group;<BR/>The causes of death also been reported;<BR/>2. The number of complications including hypotension, shock happend during treatment in integrated TCM and western medicine group was statistically significant fewer than that in the control group; but no data can be used;<BR/>3. the number of heart failure in integrated treatment group during the treatment was significantly fewer than in control group, but no data can be used.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. This was a abstract only, no whole text of the paper can be found;<BR/>2. We did not interview the original author, the evaluating was made depends on the report;<BR/>3. The authors considered that 'yiqi huoxue zhusheye' can reduces the death rate in the first week of treatment, improved partial patients' prognosis, and may preventing AMI complications including hypotension, shock, heart failure.<BR/>4. The western medicine "routine treatment" not been specified in detail.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chen-2001">
<CHAR_METHODS>
<P>"Patients were randomly allocated to two groups" was mentioned, but lack of description about the method. The original authors unable to provide the information of randomisation in detail.<BR/>Parallel design. No blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>All participants were enrolled within 2 days of the AMI onset.<BR/>61 in 'quyu huatan xiezhuo' group, M/F 46/15, 38 to 89 years, average 63.7. Of these patients, 9 were 'qixu xueyu zheng', 3 with 'both qi and yin xu zheng', 4 with 'tanshi zhuci zheng' and 45 with 'tanyu huzhu zheng'.<BR/>60 in 'yiqi huoxue' group, M/F 43/17, 34 to 90 years old, average 63.8. Of those patients, 6 with 'qixu xueyu zheng', 3 with 'both qi and yin xu zheng', 3 with 'tanshi zhucu zheng' and 48 with 'tanyu huzhu zheng'.<BR/>Severity of AMI at baseline was similar between groups.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>The basal treatment was same in two groups. All participants were treated by nitroglycerin and polarisation liquid by intravenous drip, and oral isosorbide dinitrate, captopril, aspirin enteric coated tablets, etc. Expectant treatment was used for those who with complications.<BR/>In the experimental group, used 'quyu huatan xiezhuo fang'.<BR/>In the control group, used 'yiqi huoxue fang'.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. frequency of angina pectoris;<BR/>2. change of lung moist rales;<BR/>3. change of arrhythmia.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. Wu TX telephed Professors Chen KY and Shi DZ in 23 Auguest, 2007. They don't remember the method of the randomisation and other information in detail due to the trial was conducted ten years ago. Prof. Chen said the allocation sequence seem was generated by statistician, "a random number table seem was took out from computer." <BR/>2. The paper was published in 2001, but the study was conducted during Jan. 1996 to Dec. 1998;<BR/>3. The number of death was reported in the 'Result' section although it did not be included in the 'outcomes' of 'Methods' section;<BR/>4. There is no any useful data for analysis, the description about the results were extremely simple.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-2004">
<CHAR_METHODS>
<P>"Randomly allocated patients into three groups" was mentioned, but no any description about the method of generation the sequence. TW tried to contact the authors for further information, but they could not be located. <BR/>Parallel groups. No blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Total 175 AMI patients were included from 1997 to 2002.<BR/>41 participants in group 1, 58 in group 2 and 76 in group 3. Similar in baseline includes age, sex, position of AMI, type of TCM 'zheng'.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Same basal treatment for three groups.<BR/>Group 1 used huangqi injection 20 mL and fufang danshen injection 20 mL intravenous drip twice daily for 2 weeks;<BR/>Group 2 used shenmai injection 20mL and fufang danshen injection 20mL intravenouse drip twice daily for 2 weeks;<BR/>Group 3 use basal treatment only (oxgen supply, antipaint, anticoagulation, etc, no description about the drugs in details.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Mortality.<BR/>2. Rate of severe arrhythmia.<BR/>3. Rate of heart failure.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. Although this study is included in the review, but there are some doubtful points for its reliability of randomisation, for example, the arms were not balanced (41:58:76), no any explanation for this odd rate.<BR/>2. 76 patients were included in the control group, but in the Results section, the number was became '68 patients', no any explain for this change.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-1994">
<CHAR_METHODS>
<P>"Random allocation" was mentioned but the method was not clear. Blinding not used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Danshen group included 388 participants, M/F=295/93, average age was 66+/-9 years; control group included 962 patients, M/F=712/250. Average age was 67+/-10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Danshan group: danshen injection 16~24 g with 500 mL 5% glucose injection or low molecular dextran by intravenous drip, one time a day, 7~14 days a course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality: <BR/>Danshen group: M 48/295, F 34/93;<BR/>Control group: M 158/712, F 89/250</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. The description about the randomisation in the original text was not clear: "all of the patients were randomly allocated to danshen group and control group depends on whether they used danshen injection or not". Following a telephone interview with the original author the method was judged inadequate; it's clear that the patients were given danshen injection optionally by the doctors, and the allocation to intervention or control groups followed treatment;<BR/>2. Although it was judged as a retrospective study, we still included it as it is an important study in the history of danshen for AMI, and the member hospitals of this study are high level hospitals in Shanghai, included Huashan Hospital and Zhongshan Hospital of Fudan University, Shanghai Cardiavascular Diseases Institute, Shanghai Second University of Medical Sciences Affiliated Ruijin Hospital and Renji Hospital, Xinhua Hospital. There should be some value for reference.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhang-1996">
<CHAR_METHODS>
<P>"Randomly allocated patients to two groups" was mentioned, but lack of description about the method of randomisation.<BR/>Parallel groups. No blinding.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Participants with AMI were enrolled after 30 minutes to 6 hourses of AMI onset during 1991 to early 1995. <BR/>34 participants in isosorbide dinitrate group, M/F 25/9, 33 to 82 years old (average 64.2+/-8.55), heart function I grade 29 and II grade 5 cases.<BR/>34 participants in control group, M/F 28/6, 40 to 82 years old (average 64.8+10.21), heart function I grade 30 and II grade 4 cases.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>All participants were kept given strict bed rest. Isosorbide dinitrate was given in both groups.<BR/>Isosorbide dinitrate group: 20 mg isosorbide dinitrate via intravenous drip 4~7 hours a day for 2 weeks; after 2 weeks, oral 10 mg, three times a day.<BR/>Control group: oral isosorbide dinitrate 10 mg, three times a day, fufang danshen 16 mL a day via intravenous drip for 2 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Heart function, used Killin grade.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1. TW tried to contact the original author but did not receive any further information. The impression from this paper is that it is a case records analysis not a trial due to its long duration and poor description. It is included because there is no evidence to demonstrate it is not an RCT since the original authors cannot be found;<BR/>2. The original study did not use mortality as the primary outcome, but in the Results, number of death was reported;<BR/>3. There was no description about the measure of heart function in detail, the result was reported as percentage only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>TCM - traditional Chinese medicine<BR/>'zheng' - a TCM sign</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Cha-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this article was to assess the effect of bothropsatrox antithrombusase but not danshen, the latter was used as control. The result was that the bothropsatrox antithrombusase much better than danshen on marked improvement and reducing death.<BR/>The "randomly allocated the patients" was mentioned, but it was judged as optional allocation. Dr. Cha said that her assistant developed a protocol. For the reason of unbalanced arms (14 versus 8), she explained that most patients were loss of follow-up. So, the study was judged as a non-RCT for the reason of 1. only Dr Cha was the sole author, 2. the AMI patients unable to loss of follow-up in a two weeks treatment duration. The author was interviewed in 18 June, 2007 by number 86-0755-26537163.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>The fourth version of CYG 1981.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>The fifth version of CYG 1981.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>"Randomly allocation" mentioned. But in the description about the method of randomisation, the method was described as "those not willing to accept TCM or hypersusceptibility to TCM were allocated to control group". Thus, this study was not considered as RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this article was to assess the effect of bothropsatrox antithrombusase but not danshen, the latter was used as control. And the patients included not only AMI (29 patients) but also included 163 patients with myocardial ischemia without AMI. The result was that the bothropsatrox antithrombusase was much better than danshen on marked improvement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cui-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>The outcomes of interest were not reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cui-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomly allocation was mentioned. But numbers of male and female in two groups were not balanced, in the danshen group, the number of male was 36/46, and in the control group it was 28/46, respectively. It thus be considered as an optional allocation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-CYG-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was the first clinical study about danshen formulation preparation for AMI. We do not include this article due to it was included in Chen 1984, and the use of intervention did not be described clearly.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Deng-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study aims to assess combined shenmai injection with danshen injection in the treatment of AMI, so, the shenmai was a confounder factor for assessing danshen.<BR/>Wu TX telephoned Dr. Deng, the first author, in 24 Aug. 2007, he said this paper was wrote when he was a residency ten years ago, and was a retrospective case records analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dong-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-GAM-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>The third version of CYG 1981.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Han-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-He-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this article was to assess the effect of bothropsatrox antithrombusase but not danshen, the latter was used as control. The result of reducing mortality was the bothropsatrox antithrombusase much better than danshen. <BR/>The "randomly allocated patients" was mentioned. But it actually was a retrospective study. This was know by telephoning the third author of the paper. Dr. Li Yinjun answered my question and said "we did not develop a protocol previously, we allocated the patients not strictly, just by physician's selection and "time window" of disease. The author was interviewed in 18 June, 2007.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this article was to assess the effect of bothropsatrox antithrombusase but not danshen, the latter was used as control. The result was that the bothropsatrox antithrombusase was much better than danshen on death from AMI.<BR/>"Randomly allocated the patients" mentioned, but it was actually a retrospective study. This was known by telephoning the Dr. Li, the original author. He was interviewed in 20 June, 2007.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liang-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome measures of interest not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liang-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study aims to compare the effect of combined use of urokinase with shenmai injection and danshen injection versus urokinase alone. The interesting thing was that the former was much better than the latter on vessel recanalisation rate, reducing mortality, bleedding complication, and shock, heart failure.<BR/>Wu TX telephoned Prof. Liang, the first author, in 24 Aug. 2007. Prof. Liang has promoted to as the director of Guangxi TCM Collage office. He said that this was a retrospective paper of case records analysis, no protocol was developed previously.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liang-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>"Randomly allocation" was mentioned, but the original auhtor was interviewed by telephone and it was understood that the patients were actually allocated by optional selection.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liu-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>"Large sample size, randomised, double blind controlled trial" was mentioned. But the "randomisation" was described as "randomly took drugs", of the 14,962 patients with AMI, 34.8% patients randomly used danshen injection. So, this study was considered a non-randomised controlled study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liu-2006b">
<CHAR_REASON_FOR_EXCLUSION>
<P>"Randomly allocation" was mentioned. But it was discovered telephone interview that this was not a real RCT. The patients were allocated based on patients' opinion but not by any random method.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Luo-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>The randomisation was described as "the patients were randomly allocated by the order of admission". So, it was considered as an optional allocating study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Qian-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study aims to assess the effect of integrated TCM therapy includes aupuncture and danshen multiple compound decoction and western medicine versus western medicine alone. So, the effect of danshen compound cannot be assessed separately.<BR/>Wu TX telephoned the second author, Dr. Tian ZZ on 23 Aug. 2007. Dr. Tian said that this was an analysis for case records data and no protocol was developed before study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shi-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome measures of interest not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sun-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>The randomisation was described as that the patients were allocated by the order of admission. So, the method was considered as optional allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sun-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>The randomisation was descibed as that the patients were allocated by the order of admission. So, it was considered as an optional allocating study rather than RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tang-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study aims to compare the effect of shenmai injection to danshen injection. The result was that the former is much better than the latter on the reducing mortality and improving heart function, the general improvement rate also showed that the former much higher than the latter.<BR/>Wu TX telephoned Dr. Tang, the original author, in 27 Aug. 2007. Dr. Tang did not develop a protocol previously for this study, because this was a data analysis for case records only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>The randomisation was described as that the patients were allocated according to the order of admission. So, it was considered as an optional allocation study ranther than RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this article was to assess the effect of bothropsatrox antithrombusase but not danshen, the latter was used as control. The result was that the bothropsatrox antithrombusase was much better than danshen on mortality (rate of death from AMI).<BR/>"Randomly allocated the patients" mentioned. But some of the patients used danshen injection, others used mailuoning injection in control group. It can be judged very clearly that the study did not well designed. It cannot be included because we cannot devide who was treated by danshen and who was by mailuoning, even if it is an authentic RCT. Taixiang Wu had tried to contact the author, but none of the authors can be found.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>The randomisation was described as that the patients were allocated by the order of admission. Thus, we considered it an optional allocation study rather than a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome measures of interest not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wu-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>The outcomes did not match inclusion criteria of this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xie-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this study was assess for effect of dan ao, the fufang danshen injection was used as control. The effect of dan ao was better than the control.<BR/>Wu TX telephoned Dr. Xie, the first author of the paper, in 23 Aug. 2007. Dr. Xie said that this was a retrospective study by collecting cases reports during last year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xu-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study aims to demonstrate the self-prepared formulation "Wutou ChiShizhi Tang" decoction combined with Danshen injection. So, the decoction was a confunding factor.<BR/>Wu TX telephoned Dr. Xu GH in 27 Aug. 2007. Dr. Xu said this was a case records analysis for inpatients, no protocol was developed previously.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xu-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>The randomisation was described as that the patients were allocated according to order of admission. So, the method was considered as optional allocation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ye-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this article was to assess the effect of bothropsatrox antithrombusase but not danshen, the latter was used as control. The result was that the bothropsatrox antithrombusase was much better than danshen on marked improvement and reducing death from AMI.<BR/>"Randomly allocated the patients" was mentioned. Taixiang Wu telephoned the original author, Director Ye, and understood that this was not a real RCT. The patients were allocated optionally by doctor, or depended on the price of drug, etc. The author sounds misunderstanding the concept of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yuan-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>The randomisation was described that the patients were allocated according to the order of admission. Thus, it was considered as an optional allocation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome measures of interest not reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhong-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>The outcome measures not match the including criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhou-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>The randomisation was described as that the patients were allocated according to the order of admission. Thus, it was considered as an optional allocation study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhou-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study aims to assess the effect of integrated TCM and western medicine versus western medicine alone. TCM included danshen injection, huangqi injection and shexiang baoxin wan tablet.<BR/>Wu TX telephoned Dr. Zhou. She said that this was a cases records analysis, no protocol was developed before the study. Date of interview is 23 Aug. 2007.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhu-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation allocation was mentioned in the text, but it can be judged as a non-RCT because the patients were allocated to the treatment group based on those who suit for thrombolytic thereapy, and if not, they were allocated to the control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Content of danshen compound formulations in included studies</TITLE>
<TABLE COLS="3" ROWS="9">
<TR>
<TH>
<P>Formulation</P>
</TH>
<TH>
<P>Contents</P>
</TH>
<TH>
<P>Method of using</P>
</TH>
</TR>
<TR>
<TD>
<P>Kangxingen Heji</P>
</TD>
<TD>
<P>Danshen, Cishao, Yujin, Huangqi, Dangshen, Huangjing</P>
</TD>
<TD>
<P>Oral intake while intravenous drip both Yiqi injection and Huoxue injection</P>
</TD>
</TR>
<TR>
<TD>
<P>Yiqi injection</P>
</TD>
<TD>
<P>Huangqi, Dangshen, Huangjing</P>
</TD>
<TD>
<P>Intravenous drip with Huoxue injection</P>
</TD>
</TR>
<TR>
<TD>
<P>Huoxue injection</P>
</TD>
<TD>
<P>Cishao, Danshen, Yujin</P>
</TD>
<TD>
<P>Intravenous drip with Yiqi injection</P>
</TD>
</TR>
<TR>
<TD>
<P>Fufang Danshen injection</P>
</TD>
<TD>
<P>Danshen, Jiangxiang</P>
</TD>
<TD>
<P>Intravenous drip</P>
</TD>
</TR>
<TR>
<TD>
<P>Huangqi injection</P>
</TD>
<TD>
<P>Huangqi</P>
</TD>
<TD>
<P>Intravenous drip</P>
</TD>
</TR>
<TR>
<TD>
<P>Shenmai injection</P>
</TD>
<TD>
<P>Hongshen, Maidong</P>
</TD>
<TD>
<P>intravenous drip</P>
</TD>
</TR>
<TR>
<TD>
<P>Quyu huatan xiezhuo fang</P>
</TD>
<TD>
<P>Jioudahuang 6-10g, Quangualou 10-15g, Jioubai 10g, Zhike 10g, Yujin 10g</P>
</TD>
<TD>
<P>Oral the water decoction, two times a day in one week</P>
</TD>
</TR>
<TR>
<TD>
<P>Yiqi Huoxue fang</P>
</TD>
<TD>
<P>Huangqi 10-20g, Dangshen 10-15g, Danshen 15-20g, Cishao 10-15g, Honghua 6-10g, Chenpi 6-10g</P>
</TD>
<TD>
<P>Oral the water decoction, two times a day in one week</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" NO="2">
<TITLE>Names of the herbs in three languages of included studies</TITLE>
<TABLE COLS="3" ROWS="51">
<TR>
<TH>
<P>Pingying</P>
</TH>
<TH>
<P>English</P>
</TH>
<TH>
<P>Latin</P>
</TH>
</TR>
<TR>
<TD>
<P>Danshen</P>
</TD>
<TD>
<P>Danshen Root</P>
</TD>
<TD>
<P>Radix Salviae Miltiorrhizae</P>
</TD>
</TR>
<TR>
<TD>
<P>Chishao</P>
</TD>
<TD>
<P>Red Paeony Root</P>
</TD>
<TD>
<P>Radix Paeoniae Rubra</P>
</TD>
</TR>
<TR>
<TD>
<P>Yujin</P>
</TD>
<TD>
<P>Turmeric Root-tuber</P>
</TD>
<TD>
<P>Radix Curcumae</P>
</TD>
</TR>
<TR>
<TD>
<P>Huangqi</P>
</TD>
<TD>
<P>Mongolian Milkcetch Root</P>
</TD>
<TD>
<P>Radix Astragali</P>
</TD>
</TR>
<TR>
<TD>
<P>Dangshen</P>
</TD>
<TD>
<P>Pilose Asiabell Root</P>
</TD>
<TD>
<P>Radix Codonopsis</P>
</TD>
</TR>
<TR>
<TD>
<P>Huangjing</P>
</TD>
<TD>
<P>Manyflower Solomonseal Rhizome</P>
</TD>
<TD>
<P>Rhizoma Polygonati</P>
</TD>
</TR>
<TR>
<TD>
<P>Jiangxiang</P>
</TD>
<TD>
<P>Rosewood Heart Wood</P>
</TD>
<TD>
<P>Lignum Dalbergiae Odoriferae</P>
</TD>
</TR>
<TR>
<TD>
<P>Hongshen</P>
</TD>
<TD>
<P>Ginseng</P>
</TD>
<TD>
<P>Radix Ginseng</P>
</TD>
</TR>
<TR>
<TD>
<P>Maidong</P>
</TD>
<TD>
<P>Dwarf Lilyturf Tuber</P>
</TD>
<TD>
<P>Radix Ophiopogonis</P>
</TD>
</TR>
<TR>
<TD>
<P>Jioudahuang</P>
</TD>
<TD>
<P>Rhubarb</P>
</TD>
<TD>
<P>Radix et Rhizoma Rhei</P>
</TD>
</TR>
<TR>
<TD>
<P>Quangualou</P>
</TD>
<TD>
<P>Snakegourd Fruit</P>
</TD>
<TD>
<P>Fructus Trichosanthis</P>
</TD>
</TR>
<TR>
<TD>
<P>Xiebai</P>
</TD>
<TD>
<P>Longstamen Onion Bulb</P>
</TD>
<TD>
<P>Bulbus Allii Macrostemi</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhiqiao</P>
</TD>
<TD>
<P>Bitter Orange</P>
</TD>
<TD>
<P>Fructus Aurantii</P>
</TD>
</TR>
<TR>
<TD>
<P>Yujin</P>
</TD>
<TD>
<P>Turmeric Root-tuber</P>
</TD>
<TD>
<P>Radix Curcumae</P>
</TD>
</TR>
<TR>
<TD>
<P>Chenpi</P>
</TD>
<TD>
<P>Tangerine Peel</P>
</TD>
<TD>
<P>Pericarpium Citri Reticulatae</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" NO="3">
<TITLE>Chinese medical journals handsearched</TITLE>
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Acta Chinese Medicine and Pharmacology<BR/>Beijing Journal of Traditional Chinese Medicine<BR/>China Journal of Chinese Materia Medica<BR/>China Journal of Basic Medicine in Traditional Chinese Medicine<BR/>Chinese Journal of Integrated Traditional and Western Medicine<BR/>Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care<BR/>Chinese Journal of Traditional Medical Science and Technology<BR/>Chinese Journal of Traditional &amp; Western Medicine<BR/>Chinese Traditional Patent Medicine<BR/>Chinese Traditional Patent Medicine Research<BR/>Chinese Traditional Herbal Drags<BR/>Chinese Pharmaceutical Abstracts<BR/>Clinical Journal of Anhui Traditional Chinese Medicine<BR/>Forum on Traditional Chinese Medicine<BR/>Fujian Journal of Traditional Chinese Medicine<BR/>Guang Ming Zhong Yi Journal of Traditional Chinese Medicine<BR/>Gansu Journal of Traditional Chinese Medicine<BR/>Guangxi Journal of Traditional Chinese Medicine<BR/>Guangdong Journal of Traditional Chinese Medicine<BR/>Hebei Integrated Traditional and Western Medicine<BR/>Hebei Journal of Traditional Chinese Medicine<BR/>Heilongjang Journal of Traditional Chinese Medicine<BR/>Henan Journal of Traditional Chinese Medicine and Pharmacy<BR/>Henan Journal of Traditional Chinese Medicine<BR/>Hunan Journal of Traditional Chinese Medicine<BR/>Information on Traditional Chinese Medicine<BR/>Jiangxi Journal of Traditional Chinese Medicine<BR/>Jiangshu Journal of Traditional Chinese Medicine<BR/>Jilin Journal of Traditional Chinese Medicine<BR/>Journal of Anhui College of Traditional Chinese Medicine<BR/>Journal of Beijing University of Traditional Chinese Medicine<BR/>Journal of Chengdu University of Traditional Chinese Medicine<BR/>Journal of Chinese Medicinal Materials<BR/>Journal of Emergency in Traditional Chinese Medicine<BR/>Journal of Guangzhou University of Traditional Chinese Medicine<BR/>Journal of HeNan College of Traditional Chinese Medicine<BR/>Journal of Integrated Traditional and Western Medicine<BR/>Journal of Practical Traditional Chinese Medicine<BR/>Journal of Practical Chinese Traditional Internal Medicine<BR/>Journal of Sichuan of Traditional Chinese Medicine<BR/>Journal of Traditional Chinese Medicine<BR/>Journal of Emergency Syndromes in Chinese Medicine<BR/>Journal of Nanjing college of Traditional Chinese Medicine<BR/>Journal of Hubei college of Traditional Chinese Medicine<BR/>Journal of Guiyang college of Traditional Chinese Medicine<BR/>Journal of Gansu college of Traditional Chinese Medicine <BR/>Journal of Changchun college of Traditional Chinese Medicine<BR/>Journal of Yunnan college of Traditional Chinese Medicine<BR/>Journal of Tianjin college of Traditional Chinese Medicine <BR/>Journal of Liaoning college of Traditional Chinese Medicine<BR/>Journal of Hujian college of Traditional Chinese Medicine<BR/>Journal of Jiangxi college of Traditional Chinese Medicine<BR/>Journal of Shandong college of Traditional Chinese Medicine<BR/>Journal of Hebei college of Traditional Chinese Medicine<BR/>Journal of Zhejiang college of Traditional Chinese Medicine<BR/>Journal of Shanghai University of Traditional Chinese Medicine<BR/>Journal of the Traditional Chinese Medicine<BR/>Journal of University of Traditional Chinese Medicine<BR/>Liaoning Journal of Traditional Chinese Medicine<BR/>Modern Journal of Integrated Chinese Traditional and Western Medicine<BR/>Modern Traditional Chinese Medicine<BR/>Neimongol Journal of Traditional Chinese Medicine<BR/>New Journal of Traditional Chinese Medicine<BR/>Pharmacology and Clinics of Chinese Materia Medica<BR/>Research of Traditional Chinese Medicine<BR/>Shanxi Journal of Traditional Chinese Medicine<BR/>Shanxi Journal of Traditional Chinese Medicine<BR/>Shandong Journal of Traditional Chinese Medicine<BR/>Shanghai Journal of Traditional Chinese Medicine<BR/>Shenzhen Journal of Integrated Traditional and Western Medicine<BR/>Tianjin Journal of Traditional Chinese Medicine<BR/>Traditional Chinese Medicine Research<BR/>Xinjiang Journal of Traditional Chinese Medicine<BR/>Yunnan Journal of Traditional Chinese Medicine and Materia Medica<BR/>Zhejiang Journal of Traditional Chinese Medicine<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Danshen compunds + western medicine versus western medicine</NAME>
<DICH_OUTCOME CHI2="12.318979513351877" CI_END="0.8422766706657382" CI_START="0.5779549268857731" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6977090737637064" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="473" I2="43.17711144488001" I2_Q="50.291239285855106" ID="CMP-001.01" LOG_CI_END="-0.07454522820725132" LOG_CI_START="-0.23810602969032124" LOG_EFFECT_SIZE="-0.1563256289487863" METHOD="PETO" NO="1" P_CHI2="0.09054515245728534" P_Q="0.06041870787375858" P_Z="1.7929863709057015E-4" Q="12.070306951532324" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1204" TOTAL_2="2247" WEIGHT="700.0" Z="3.7465285058768525">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Danshen</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.24867256181954955" CI_END="0.752701915979928" CI_START="0.27608964429421573" DF="1" EFFECT_SIZE="0.45586533564471976" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="46" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.12337697848087104" LOG_CI_START="-0.5589498827856665" LOG_EFFECT_SIZE="-0.34116343063326876" NO="1" P_CHI2="0.6180113549857353" P_Z="0.002138494672026759" STUDIES="2" TAU2="0.0" TOTAL_1="327" TOTAL_2="327" WEIGHT="100.0" Z="3.07029216131144">
<NAME>Prospective studies</NAME>
<DICH_DATA CI_END="0.7684100313882789" CI_START="0.2264548908974931" EFFECT_SIZE="0.41714531020086026" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="32" LOG_CI_END="-0.11440697417455757" LOG_CI_START="-0.6450182951318081" LOG_EFFECT_SIZE="-0.37971263465318283" ORDER="629" O_E="-9.0" SE="0.3116837164986884" STUDY_ID="STD-Chen-1984a" TOTAL_1="215" TOTAL_2="215" VAR="10.293706293706293" WEIGHT="67.38584645956205"/>
<DICH_DATA CI_END="1.3177672210823994" CI_START="0.22757868386128366" EFFECT_SIZE="0.5476273640071994" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="0.1198387004492708" LOG_CI_START="-0.6428684185289747" LOG_EFFECT_SIZE="-0.26151485903985194" ORDER="630" O_E="-3.0" SE="0.4480179371489502" STUDY_ID="STD-Chen-1984b" TOTAL_1="112" TOTAL_2="112" VAR="4.982062780269058" WEIGHT="32.614153540437954"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.4931399697652035" CI_START="0.4171469363620862" DF="0" EFFECT_SIZE="1.5137524597488445" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.7398206653461703" LOG_CI_START="-0.37971094164249014" LOG_EFFECT_SIZE="0.18005486185184005" NO="2" P_CHI2="1.0" P_Z="0.5284040733752329" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="0.630444093347542">
<NAME>'quyu huatan xiezhuo' fang formulation vs 'yiqi huoxue' fang formulation</NAME>
<DICH_DATA CI_END="5.4931399697652035" CI_START="0.4171469363620862" EFFECT_SIZE="1.5137524597488445" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7398206653461703" LOG_CI_START="-0.37971094164249014" LOG_EFFECT_SIZE="0.18005486185184005" ORDER="631" O_E="0.9586776859504136" SE="0.6576184077159702" STUDY_ID="STD-Chen-2001" TOTAL_1="61" TOTAL_2="60" VAR="2.312342053138447" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9662935728061784" CI_START="0.06363731120177972" DF="0" EFFECT_SIZE="0.24797646018311165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-0.014890909112300725" LOG_CI_START="-1.1962881784110484" LOG_EFFECT_SIZE="-0.6055895437616746" NO="3" P_CHI2="1.0" P_Z="0.044497625920818365" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="76" WEIGHT="100.0" Z="2.009372674259631">
<NAME>Shenmai injection + Fufang Danshen injection vs placebo</NAME>
<DICH_DATA CI_END="0.9662935728061784" CI_START="0.06363731120177972" EFFECT_SIZE="0.24797646018311165" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.014890909112300725" LOG_CI_START="-1.1962881784110484" LOG_EFFECT_SIZE="-0.6055895437616746" ORDER="632" O_E="-2.8955223880597014" SE="0.6939586039968829" STUDY_ID="STD-Li-2004" TOTAL_1="58" TOTAL_2="76" VAR="2.076504471247176" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3363387662194381" CI_START="0.07820789980069513" DF="0" EFFECT_SIZE="0.3232835416909966" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.12591656715894092" LOG_CI_START="-1.1067493765236665" LOG_EFFECT_SIZE="-0.4904164046823628" NO="4" P_CHI2="1.0" P_Z="0.1188676396934173" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="76" WEIGHT="100.0" Z="1.5595441660916778">
<NAME>Huangqi injection + Fufang Danshen injection vs placebo</NAME>
<DICH_DATA CI_END="1.3363387662194381" CI_START="0.07820789980069513" EFFECT_SIZE="0.3232835416909966" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="0.12591656715894092" LOG_CI_START="-1.1067493765236665" LOG_EFFECT_SIZE="-0.4904164046823628" ORDER="633" O_E="-2.1538461538461537" SE="0.7240740771139933" STUDY_ID="STD-Li-2004" TOTAL_1="41" TOTAL_2="76" VAR="1.9073658437053658" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9731832756511166" CI_START="0.49673252276032964" DF="0" EFFECT_SIZE="0.695278205916409" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="158" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="-0.011805363114465837" LOG_CI_START="-0.30387740434351357" LOG_EFFECT_SIZE="-0.1578413837289897" NO="5" P_CHI2="1.0" P_Z="0.03414078793267686" STUDIES="1" TAU2="0.0" TOTAL_1="295" TOTAL_2="712" WEIGHT="100.00000000000001" Z="2.1184049392538635">
<NAME>Retrospective study (male)</NAME>
<DICH_DATA CI_END="0.9731832756511166" CI_START="0.49673252276032964" EFFECT_SIZE="0.695278205916409" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="158" LOG_CI_END="-0.011805363114465837" LOG_CI_START="-0.30387740434351357" LOG_EFFECT_SIZE="-0.1578413837289897" ORDER="634" O_E="-12.34756703078451" SE="0.17156456279786395" STUDY_ID="STD-Wang-1994" TOTAL_1="295" TOTAL_2="712" VAR="33.97385463629422" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.02863030252894" CI_START="0.5941134373218275" DF="0" EFFECT_SIZE="0.7817436183102873" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="247" I2="0.0" ID="CMP-001.01.06" LOG_CI_END="0.01225931410062669" LOG_CI_START="-0.22613062488517827" LOG_EFFECT_SIZE="-0.10693565539227572" NO="6" P_CHI2="1.0" P_Z="0.07868289838722804" STUDIES="1" TAU2="0.0" TOTAL_1="388" TOTAL_2="962" WEIGHT="100.0" Z="1.7583798554898502">
<NAME>Retrospective study (female)</NAME>
<DICH_DATA CI_END="1.02863030252894" CI_START="0.5941134373218275" EFFECT_SIZE="0.7817436183102873" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="247" LOG_CI_END="0.01225931410062669" LOG_CI_START="-0.22613062488517827" LOG_EFFECT_SIZE="-0.10693565539227572" ORDER="635" O_E="-12.557037037037034" SE="0.1400314302094914" STUDY_ID="STD-Wang-1994" TOTAL_1="388" TOTAL_2="962" VAR="50.997507559427746" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="13.21278856203217" CI_START="0.7062034870725167" DF="0" EFFECT_SIZE="3.054655030680057" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" ID="CMP-001.01.07" LOG_CI_END="1.1209944852373195" LOG_CI_START="-0.15107014232005697" LOG_EFFECT_SIZE="0.48496217145863124" NO="7" P_CHI2="1.0" P_Z="0.13506218960756228" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="34" WEIGHT="100.0" Z="1.4944341180973262">
<NAME>Isosorbide dinitrate vs isosorbide dinitrate plus Danshen injection</NAME>
<DICH_DATA CI_END="13.21278856203217" CI_START="0.7062034870725167" EFFECT_SIZE="3.054655030680057" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.1209944852373195" LOG_CI_START="-0.15107014232005697" LOG_EFFECT_SIZE="0.48496217145863124" ORDER="636" O_E="2.0" SE="0.7472170590486632" STUDY_ID="STD-Zhang-1996" TOTAL_1="34" TOTAL_2="34" VAR="1.791044776119403" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="99" TOTAL_2="152" WEIGHT="0.0" Z="0.0">
<NAME>Rate of severe arrhythmia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="26" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Fufang Danshen injection + Huangqi injection vs placebo</NAME>
<DICH_DATA CI_END="0.6665912131707828" CI_START="0.11792784840293115" EFFECT_SIZE="0.2803741563224578" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="26" LOG_CI_END="-0.1761404153928508" LOG_CI_START="-0.9283836251035839" LOG_EFFECT_SIZE="-0.5522620202482174" ORDER="637" O_E="-6.512820512820513" SE="0.4418713850480272" STUDY_ID="STD-Li-2004" TOTAL_1="41" TOTAL_2="76" VAR="5.12163050624589" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="26" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>Fufang Danshen injection + Shenmai injection vs placebo</NAME>
<DICH_DATA CI_END="0.9147047328417622" CI_START="0.19685879409518495" EFFECT_SIZE="0.4243438118558908" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" LOG_CI_END="-0.03871907379377678" LOG_CI_START="-0.7058451795950905" LOG_EFFECT_SIZE="-0.3722821266944336" ORDER="638" O_E="-5.582089552238806" SE="0.39187317687517464" STUDY_ID="STD-Li-2004" TOTAL_1="58" TOTAL_2="76" VAR="6.511918021831143" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.292528623946899" CI_END="0.7638976149498453" CI_START="0.10655386512282476" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.2853002688940432" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="16" I2="22.63227432856581" I2_Q="22.63227432856577" ID="CMP-001.03" LOG_CI_END="-0.11696484592956363" LOG_CI_START="-0.9724307921152452" LOG_EFFECT_SIZE="-0.5446978190224043" METHOD="PETO" NO="3" P_CHI2="0.25558259515856063" P_Q="0.25558259515856063" P_Z="0.012563024774082497" Q="1.2925286239468983" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="99" TOTAL_2="152" WEIGHT="200.0" Z="2.495921930034853">
<NAME>Rate of severe heart failure</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8892438483188723" CI_START="0.12630676190568474" DF="0" EFFECT_SIZE="0.48849183507136673" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.27628801675959325" LOG_CI_START="-0.8985733986155579" LOG_EFFECT_SIZE="-0.3111426909279823" NO="1" P_CHI2="1.0" P_Z="0.2992103216238632" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="76" WEIGHT="100.0" Z="1.0381283448260923">
<NAME>Fufang Danshen injection + Huangqi injection vs placebo</NAME>
<DICH_DATA CI_END="1.8892438483188727" CI_START="0.12630676190568468" EFFECT_SIZE="0.48849183507136673" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.27628801675959336" LOG_CI_START="-0.898573398615558" LOG_EFFECT_SIZE="-0.3111426909279823" ORDER="639" O_E="-1.5042735042735043" SE="0.6901194110491636" STUDY_ID="STD-Li-2004" TOTAL_1="41" TOTAL_2="76" VAR="2.099672276506936" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6542881348109584" CI_START="0.03695646167182398" DF="0" EFFECT_SIZE="0.15549975683733525" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.1842309553440806" LOG_CI_START="-1.4323096161846902" LOG_EFFECT_SIZE="-0.8082702857643853" NO="2" P_CHI2="1.0" P_Z="0.011129984234769205" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="76" WEIGHT="100.0" Z="2.5385910352879697">
<NAME>Fufang Danshen injection + Shenmai injection vs placebo</NAME>
<DICH_DATA CI_END="0.6542881348109586" CI_START="0.03695646167182398" EFFECT_SIZE="0.15549975683733525" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.18423095534408043" LOG_CI_START="-1.4323096161846902" LOG_EFFECT_SIZE="-0.8082702857643853" ORDER="640" O_E="-3.462686567164179" SE="0.7331275834667843" STUDY_ID="STD-Li-2004" TOTAL_1="58" TOTAL_2="76" VAR="1.8605480062374693" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>